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ABSTRACT
Interferons (IFNs) are a common biological treatment option for many cancers as well as 
for human papillomavirus (HPV)-associated diseases, but current IFN treatments have not been 
optimized as disease progression subsists and treatment-limiting side effects still exist. IFN 
kappa (IFN-k), a novel type I IFN, principally expressed in kératinocytes, may offer 
improvements in current IFN treatment regimes. The goal of the current study was to 
characterize the IFN-P, IFN-y and IFN-k mRNA levels in normal, dysplastic and cervical 
carcinoma tissue, as well as microdissected cervical epithelium and stroma, to determine the 
effects of HPV on IFN-k gene expression in relation to other common IFNs. Optimal sample 
handling techniques for tissue preparation and storage, RNA extraction and quantification, and 
target gene detection are crucial for reliable gene expression analysis. Methods for measuring 
mRNA levels of low-expressing genes, such as IFNs, in human cervical samples are not 
described in the scientific literature. Thus, we obtained normal and dysplastic frozen and 
formalin-fixed cervical biopsies from colposcopy. Histopathological diagnoses were performed 
by one pathologist. Cervical kératinocytes and stroma were isolated using laser capture 
microdissection. Immortalized kératinocytes transduced with or devoid of an HPV oncogene 
were used for initial method development. Human kératinocytes, cervical cancer-derived cell 
lines as well as patient-derived peripheral blood lymphocytes were used for supportive 
experiments. Here we report optimal methods for gene expression analysis of IFNs in cervical 
tissue as well as the comprehensive analysis of whole tissue and cell-specific IFN-y, -(3 and -K  
gene expression in HPV-associated cervical disease. IFN-K gene expression increased with 
disease progression, while IFN-(3 gene expression decreased with disease progression. IFN-y 
levels remained unchanged despite HPV infection. Furthermore, IFN-K expression in cervical
13
stroma cells was induced upon HPV infection, implicating the involvement of cervical stroma 
cells in the HPV-associated increase in IFN-k expression. The described optimized methods 
could lead to improvements in immunological profiling and disease diagnosis, techniques 
without which IFN-k would remain undetectable in cervical samples. Further, characterization of 
the IFN immune profile in patients with different stages of HPV-associated cervical disease, with 
emphasis on the novel IFN-k, could help develop patient-tailored IFN treatment regimes that 
lead to the promotion of viral regression in women suffering from cervical disease.
14
1.0 INTRODUCTION
1.1 Cervical Cancer and Cervical Precursor Lesions
Cancer of the uterine cervix is one of the most common malignancies in women 
worldwide. Approximately 1,400 Canadian women are diagnosed with cervical cancer each year; 
however, this disease is much more prevalent in developing countries. Cervical cancer and its 
precursor lesions, cervical intraepithélial neoplasia (CIN) 1-3, are caused by high-risk human 
papillomavirus (HPV) infection^ HPV infection is required for the maintenance and propagation 
of the malignancy, but the infection is usually transient and most women can effectively clear it, 
resulting in lesion regression. A small percentage of women, however, cannot clear the infection, 
resulting in a persistent HPV infection which may lead to the formation of a cervical lesion and 
in some cases cervical cancer.
1.2 Human Papillomavirus
HPV is a DNA virus consisting of an 8,000 base pair, closed, double stranded, circular 
genome (Figure 1), surrounded by an outer shell consisting of capsid proteins but lacking an 
envelope. The HPV genome consists of three major regions: the early region consisting of early 
genes encoding proteins involved in viral transcription and transformation of the host cell, the 
late region encoding late genes encoding the capsid proteins and the regulatory element (LCR) 
required for viral transcription and replication. HPV directly infects the squamous epithelial cells 
of skin and mucosa and, in the cervix, initially infects the basal proliferating layer of the 
squamous epithelium present at the squamo-columnar junction where it is believed the virus 
enters at a site of wounding (reviewed in ref#2).
The viral life cycle relies heavily on the differentiation program of the host squamous 




Figure 1. HPV genome. Circular genome consisting of early genes, late genes and a regulatory 
region. The early genes consist of E l, E4, E6, E7, the late genes consist of LI and L2 and the
regulatory element (LCR) stands alone.
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plasmid and replicates itself approximately once every cell cycle by hijacking the host 
replication machinery^. As the basal cells divide, daughter cells destined for more superficial 
layers of the epithelium stratify and differentiate (Figure 2). It is in the differentiated cells that 
the virus enters the productive stage of its life cycle where a high copy number of viral DNA is 
produced and capsid production and viral assembly occurs"*. Expression of HPV capsid proteins, 
namely LI and L2, allows for the assembly of replicated viral DNA into virions. Production of 
virions constitutes a means of multiple host infections and meaintenance of HPV DNA within 
the host. Interestingly, the development of prophylactic vaccines against HPV is based on the 
effects of LI exposure to the host. The LI capsid protein alone is able to form virus-like particles 
in the host that elicits production of B cell and T cell responses specific to HPV. These responses 
generate HPV type-specific neutralizing antibodies that, after immunization, would prevent 
persistent HPV infection. Maintenance of viral DNA in the host occurs through chromosomal 
viral genome integration during the progression of preneoplastic lesions to invasive cervical 
carcinoma"*.
Many types of HPVs exist. Low risk types, such as HPV 6 and 11, are associated with 
benign lesions or genital warts, whereas the high risk types, such as HPV 16, 18, 31 and 33 are 
associated with anogenital and oropharyngeal cancers as well as > 90% of cervical cancers^. The 
involvement of papillomavirus DNA in cervical cancer was first described in 1974*. The ability 
of HPV to cause cancer is due to two oncoproteins it harbors. HPV E6 and E7 oncogenes are 
requisite factors for the malignant phenotype of HPV-positive cervical cancer cells^. In a healthy 
host cell, protein 53 (TP53; p53) is involved in the regulation of DNA repair, cellular apoptosis 
and cell cycle regulation. Upon HR HPV infection, HPV E6 renders p53 nonfunctional by 
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Figure 2. HPV viral life cycle and cervical epithelium. The basal membrane separates 
epithelium from stroma and is where the basal layer of epithelium rests which is the site o f HPV 
infection via microlesions. Increasing vertical layers represents differentiating epithelial cells 
where enhanced viral DNA replication and particle formation occur. In the superficial epithelial 
layers is where the formed viral particles are released (ref #2).
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cell proliferation and initiate programmed cell death in the presence of a stressor. Similarly, in a 
healthy cell, the Retinoblastoma (Rb) protein is involved in the regulation of normal cell cycle 
progression (Figure 3). Upon HR HPV infection, HPV E7 binds to Rb, rendering it 
nonfunctional and unable to regulate the cell cycle, resulting in the uncontrolled proliferation of 
squamous epithelium. Despite other cell cycle regulators that act to maintain normal levels of 
cellular proliferation, such as p i (Figure 3), without a functional Rb protein the cell cycle 
cannot be regulated. Incidentally, it has been proposed that p i 6 is an accurate biomarker for HR 
HPV infection in cervical squamous epithelium due to its upregulation upon HR HPV infection.
1.3 Interferons
Interferons (IFNs) belong to the family of vertebrate cytokines and, upon microbial 
infection, are produced by many cells and specialize in antitumor®, antiviral^ and 
immunostimulatory*° activity. IFNs were first described in 1957 when researchers noticed an 
interference effect caused by heat-inactivated influenza virus on the growth of the live virus; 
later described as a factor which blocks viral infection^. Type I IFNs include IFN alpha (IFN-a), 
IFN beta (IFN-P), IFN-omega (IFN-co), IFN-epsilon (IFN-e) and IFN kappa (IFN- k )**, while 
type II IFNs consist solely of IFN-y*^- Type I IFNs can be produced by all nucleated cells in 
response to microbial infections. Type I IFNs lack introns and their genes are located on the 
short arm of chromosome 9* .̂ There are 13 different IFN-a genes but only one IFN-p and IFN- 
co**. Type I IFNs are strongly induced in virally infected cells and stimulate genes involved in 
fighting the infection, which acts to protect nearby uninfected cells. Type I IFNs also exhibit an 
ability to induce apoptosis in infected cells so as to limit the spread of the virus*"*.
19
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Figure 3. The cell cycle, Rb and Rb exerts its action at the end of the G1 phase (prior
to S phase entry) of the cell cycle and p l6  acts as a negative regulator of Rb function during the 
same phase.
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The type II IFN, IFN-y, is an immunomodulatory cytokine, mainly produced by 
lymphocytes and natural killer cells, and comprises the effective form of innate immunity against 
invading pathogens by being involved in the upregulation of MHC molecules*^, by promoting 
the local formation of inflammatory agents, such as monocytes and activated T lymphocytes'®. 
Unlike type I IFNs, IFN-y is encoded by a single gene present on chromosome 12. Similar to 
IFN-P, IFN-y only has one active protein form; however, in contrast to type I IFNs, antigen- 
MHC complexes and other cytokines, such as IL-12 and IL-18, stimulate type II IFNs 
production*'*. Together the type I and II IFNs represent a bridge between innate and adaptive 
immunity by inducing a plethora of antiviral effects against invading pathogens.
IFNs, either used alone or in combination with other treatments, are an approved therapy 
for many diseases. IFN-a has shown some success for the treatment of chronic hepatitis B, 
hepatitis C and human herpes virus-8 infections as well as a small percentage of metastatic renal­
cell carcinomas and has been employed in the treatment of HPV-associated conditions such as 
recurrent respiratory papillomatosis*® and genital warts*^. IFN-P, in conjunction with other 
biological agents, is used with much success for treating multiple sclerosis, as it can decrease the 
rate of disease relapse and progression^®. IFN-y has only been approved for treatment of chronic 
granulomatus disease, a rare congenital disorder. Furthermore, type I IFNs are a standard 
treatment for melanoma and some solid tumors^*. Despite the proven therapeutic utility of type I 
IFNs, the existence of substantial side effects, such as fatigue, fever, malaise, myalgia and 
anemia^^ may limit the therapeutic potential of the type I IFNs currently in use. It is well 
documented that side effects from IFN treatment have been substantial enough to force patients 
to reduce or discontinue IFN therapy^ '̂^®.
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1.4 Novel Interferon Kappa
Recently, a novel type I IFN, IFN-kappa (IFN-k), that is expressed primarily in 
kératinocytes”  has been identified. IFN-k exhibits 30% homology to other type I subtypes, 
however its gene is located on the short arm of chromosome 9, adjacent to the type I gene 
cluster”  and is only expressed in epidermal kératinocytes, monocytes and monocyte-derived 
dendritic cells” . IFN-k, like other type I IFNs, contains a series of conserved cysteine residues in 
its amino acid sequence”  as well as GAAANN elements which act to mediate IRF binding to its 
promoter in response to viral infection^^. Unlike other IFNs, the IFN-k gene contains an intron 
within the 3’ untranslated region”  and the protein is slightly larger than other IFNs, where its 
mature size is 180 amino acids compared to 166 amino acids for IFN a and P” . IFN-k exhibits 
similar antiviral activity and utilizes the same receptor and regulatory element as other type I 
IFNs but differs in its expression and signaling characteristics. IFN-k and IFN-a display similar 
transcriptional activation potential, as transfection of either in HeLa cells resulted in a 20-fold 
increase in interferon stimulated regulatory element (ISRE) compared to a control^®. Like other 
type I IFNs, transfection of IFN-K resulted in an increase in mRNA levels of the interferon- 
stimulated genes (ISGs), IFN-induced GTPase (MxA), protein kinase R (PKR) and 
oligoadenylate synthetases (GAS)” . Additionally, IFN-k and IFN-a both sustain cell viability 
against encephalomyocarditis (EMCV) infection in HeLa cells^®. Following EMCV infection, the 
cell viability of HeLa cells is directly related to the number of cells expressing IFN-k, whereas 
viability is independent of the number of cells expressing IFN-a, indicating that the antiviral 
activity of IFN-k is cell-associated^®. Furthermore, data suggest that monolayer cells only in 
close proximity to IFN-K-expressing cells are viable following EMCV infection^®, suggesting 
that IFN-k signals in a discrete, autocrine manner different than the paracrine signaling usually
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exerted by IFNs. Utilizing an antibody against the type I IFN receptor blocked IFN binding and 
completely abolished IFN-k signaling” , indicating that IFN-k signaling is initiated by the same 
receptor complex as the other type I IFNs. In addition, northern blot analysis of IFN-K mRNA 
levels in immortalized skin kératinocytes revealed that unlike EFN-P, IFN-K mRNA is present in 
resting kératinocytes and, like other IFNs, is significantly upregulated upon dsRNA treatment” , 
indicating that IFN-k is present at a basal level in cells but can also be induced following dsRNA 
exposure. In a recent investigation into human cutaneous skin, IFN-k was found to be strongly 
expressed in allergic contact dermatitis and planus-affected skin, completely absent in healthy 
skin and weakly expressed in psoriatic and atopic dermatitis epidermis^^. Both IFN-K and -P 
stimulate cytokine production from both monocytes and dendritic cells and both bind to heparin, 
a member of the glycosaminoglycan family®®.
Despite having many similarities to other type I IFNs in terms of signaling pathways and 
the activation of downstream antiviral genes, IFN-K represents a unique antiviral protein that is 
highly specific to epithelial cells and displays discrete signaling. Due to the distinct nature of its 
activity and overall potency of its antiviral effects, IFN-k could lead to an improvement in 
existing IFN treatment regimes by delivering more precise, local antiviral treatment, which may 
limit side effects.
1.5 Interferon Induction Pathways
1.5.1 Extracytoplasmic Pathogen Sensors
The known extracytoplasmic pathway for IFN induction during RNA viral infection 
consists of the pattern recognition receptor (PRR/TLR) system (Figure 4). Toll-like receptors 
(TLRs) are membrane proteins, typically expressed on cells of the innate immune system, which 
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Figure 4. Interferon induction and signaling pathways. A microbial agent is recognized by an 
initial cells triggering a signaling cascade which leads to IFN gene transcription (left). Translated 
IFN proteins act on subsequent cells by binding to the IFN receptor and activating signaling 
cascades which lead to the activation of ISGs (right) (ref #109).
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More specifically, TLRs recognize most types of viruses as well as components of gram-negative 
bacteria. It is important to note that while many TLRs are activated by single or double stranded 
RNA, DNA viral components can also activate TLRs. TLR9 senses DNA viruses, specifically 
DNA CpG motifs^’, and it has recently been demonstrated that TLR3 is upregulated in response 
to HPV in ex vivo cervical kératinocytes (DeCarlo et a l,  unpublished data). Some TLRs, such as 
TLR4, are present on the cell surface, however TLR 3,7,8 and 9 are localized in endosomes and 
recognize viral ligands once they are internalized.
1.5.2 Cytoplasmic Pathogen Sensors
The known cytoplasmic pathway for IFN induction during RNA viral infection consists 
of the retinoic acid inducible gene-1/melanoma differentiation associated gene 5 (RIG-1/Mda5) 
system and involves the intracellular recognition of viruses. Upon viral infection, dsRNA 
interacts with RNA helicase proteins which contain a caspase-reciuiting domain (CARD). These 
helicases then interact with a mitochondrial resident protein which in turn interacts with the 
CARDS of the retinoic acid-inducible protein (RIG-1)^^ and the melanoma differentiation 
antigen 5 (MDA5). It is the CARD domains which are responsible for eliciting downstream 
signaling that leads to activation of downstream transcription factors governing IFN gene 
expression^^.
Together, either extracytoplasmic or cytoplasmic pathogen sensors lead to activation of 
IFN regulators, such as NF-kB (Nuclear factor of kappa B) and IRF3 (Interferon regulatory 
factor-3), both of which are involved in IFN gene transcription regulation. Adaptor proteins, such 
as the interferon beta promoter stimulator 1 (IPS-1), mediate IFN gene upregulation by Mda and 
RIG through activation of IRF-3, IRF-7 and NF-kB transcription factors^^. The IFN-induction 
pathways have not been characterized for IFN-k.
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1.6 Interferon Regulatory Factors
Nine cellular IRF genes have been identified and their proteins represent major molecules 
involved in innate immunity; however only four forms play a role in IFN-mediated anti-viral 
defense (reviewed in ref#34). IRF-3 and IRF-7 are involved in a positive feedback loop 
responsible for massive IFN induction during a viral infection. Once pathogen sensor pathways 
elicit IRF-3, it translocates to the nucleus and induces IFN-(3 transcription (Figure 4). The 
activation of IFN leads to the induction of IRF-7 expression through ISRE activation, which 
ultimately leads to a further increase in IFN-P gene activation and more production of ERF-7^ .̂ 
Other IRF molecules play a vital role in IFN gene activation. IRF-9 is a component of 
ISGF3/p48 and is involved in the stimulation of IS G (Interferon Stimulated Gene) 
transcription^^, while fRF-1 is a transcription factor present on the IFN-P promoter^^ and is 
essential in the activation of various immune cells. While, IRF-1 has been shown to be induced 
upon IFN-k treatment^ \  similar to results found with IFN-p and IFN-y treatment^*, to this date 
no other transcription factors have been associated with IFN-k upregulation.
1.7 Interferon Signaling Pathways
Following IFN induction, the intracellular signaling cascades result in the transcription of 
genes responsible for anti-viral activity (Figure 4). Type I IFNs are associated with the IFNot/p 
receptor (IFNAR) which is composed of the two subunits IFNAR-1 and IFNAR-2^^, whereas the 
IFN-y receptor (IFNGR) is composed of two subunits IFNGR-1 and IFNGR-2^^. Activation of 
the IFN receptor complex by IFN binding results in the activation of the JAK-STAT pathway. 
These pathways differ slightly for type I and type II IFNs. The phosphorylation of STAT 
molecules in either pathway results in the formation of transcriptional activation complexes. The 
ISGF3 activation complex for type I IFNs, composed of STATl, STAT2 and another
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transcription factor, most commonly IRF-9 or p48" °̂, binds to the IFN stimulated regulatory 
elements (ISRE) of downstream genes. In the type II IFN response, a separate activation 
complex is involved in binding to the IFN-y activated sequences (GAS) present on downstream 
genes'^\ Binding of ISRE or GAS results in the subsequent transcriptional activation of ISGs, 
which then evoke the anti-viral, anti-tumor and immunomodulatory activities associated with 
IFNs.
1.8 Interferon Stimulated Genes
There are approximately 100 different ISGs, some of which represent genes most 
downregulated upon HR HPV infection"^^. Two well studied IFN-inducible proteins are protein 
kinase R (PKR) and 2’-5’ oligoadenylate synthetases (OAS). PKR autophosphorylates when 
activated by dsRNA and continues to phosphorylate downstream substrates, one of which is the 
alpha subunit of initiation factor eIF2'^ .̂ eIF2 forms a complex with GDP (eIFs-GDP-eIF2B), 
which results in an inhibition of cellular translation and termination of viral replication. OAS, 
another ISG, also recognizes dsRNA and in turn activates an endoribonuclease which degrades 
both viral and cellular RNAs"̂ "̂ . OAS is significantly downregulated upon cellular exposure to 
HPV 16 E6/E7 viral vectors'*^. Furthermore, many ISGs responsible for antiviral activity are also 
significantly perturbed by HPV, including p53, Rb, the TLR adaptor molecule MyD88, IFN- 
induced proteins IFITl, IFI54 and ISG 15 and the IFN induced GTPase Mx"̂ .̂ The human MxA 
GTPase exerts an antiviral function by interfering with viral protein transport within the celf^.
1.9 Human Papillomavirus and Interferon Interactions
HPV directly interacts with and inhibits the function of many molecules involved in the 
interferon pathways which may, in part, explain why HPV infections can be sustained in the host 
without initiating an effective immune response. HPV interacts with both IFN gene regulation as
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well as downstream IFN-elicited pathways. It has been shown that the HPV 16 E7 protein inhibits 
type I IFN signaling by binding to p48, part of the IFN transcriptional activation complex"^^. The 
E7 protein can also recruit a histone deacetylase to the IFN-|3 promoter, blocking ERF-1 
activation and in turn EFN-(3 transcription"^^. HPV 16 E6 has also been found to impede IFN-(3 
transcription by binding and inhibiting IRF-3"^*. HPV 18 has been shown to eliminate expression 
of p48 as p48 transcription was absent in tumorigenic cervical cells^^. HPV 16 E6 protein has 
been found to degrade p53 by using a ubiquitin proteolytic pathway"^^. Therefore, E6-positive 
cells lose cell cycle regulation of p53, specifically at the G1 checkpoint^°, rendering these cells 
resistant to p53-mediated apoptosis^\ The HPV E6 protein represses p53 function by targeting 
CBP/p300 by inhibiting the CBP transcription adaptor motif TRAM in an interaction involving 
HPV E6 zinc fingers and CBP TRAM residues^^. Furthermore, the HPV 18 E6 oncoprotein 
impairs JAK/STAT activation by EFN-a^^. These interactions demonstrate that HPV has evolved 
the ability to evade immune detection by inhibiting both the production and action of IFNs. 
However, it should be noted that the effects of HPV on IFN-K regulated and elicited pathways 
are currently unknown. Interestingly, in a recent study analyzing the effects of IFN treatment on 
HPV oncogene expression in cell lines, it was found that EFN-a, -|3 and -y were effective at 
decreasing the level of oncogene transcripts in HPV 18+ HeLa cells and IFN-y exerted the same 
effect in HPV 16+ CaSki cells "̂ .̂ This evidence demonstrates that despite the detrimental 
interactions of HPV on the IFN pathways, IFN treatment can still be a useful option for HPV- 
associated cervical disease, including cervical carcinoma.
1.10 Interferons and Cervical Disease
Multiple studies exist that attempt to correlate IFN expression alteration with cervical 
cancer. HPV 16 has been shown to inhibit both EFN-a and IFN-(3 in HPV 16 + kératinocytes"^^.
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Similarly, previous studies have concluded that IFN-y expression was significantly decreased in 
invasive carcinoma biopsies compared to premalignant tissue^^ and at lower frequencies in 
carcinoma versus dysplastic cervical tissue^^. Further, IFN-y expression has been shown to be 
completely absent in a subset of cancer patients (stage II or III) displaying no defect in T cell 
infiltration, indicating that the alteration of IFN-y expression in these patients could be due to 
deactivation of T cells^^. In a recent study conducted on TNF-a mediated IFN-(3 signaling in 
cervical carcinoma cells, it was elucidated that TNF-a, a strong inducer of IFN-p, was unable to 
induce IFN-P activity in tumorigenic cells^*. This indicates that the cross-talk between these two 
molecules is disturbed in cervical cancer^*. In addition, IFN-p and IFN -a transcription has been 
shown to be downregulated in kératinocytes infected with HPV 16"̂ .̂ While convincing evidence 
exists illustrating the inhibitory effects of HPV on IFNs in cervical tissue, however, to date, there 
have been no investigations into IFN-k expression in the context of cervical carcinoma.
1.11 Method Development
The use of quantitative real-time polymerase chain reaction (qRT-PCR) for the molecular 
analysis of disease is a powerful and widely used tool. Extraction of high-quality RNA for use in 
gene expression analysis techniques such as reverse transcription (RT), qRT-PCR and cDNA 
microarrays is of great importance. While obtaining high-quality RNA from cell lines is 
relatively straightforward, the complexity and heterogeneity of human tissue presents 
considerable challenges for linking gene expression patterns with disease state. Nonetheless, ex 
vivo studies utilizing human tissue samples are important for the validation of in vitro work and 
to closely mimic relevant biological processes. In recent years, the introduction of laser capture 
microdissection (LCM) has greatly enhanced the specificity of the molecular analysis of cell 
types within a sample. However, obtaining sufficient quantities of high quality RNA from
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microdissected cells represents an additional obstacle. Performing reliable gene expression 
studies requires stringent monitoring of sample integrity during sample preparation, RNA 
extraction and qRT-PCR steps.
Poor tissue storage conditions can degrade RNA^^. Formalin-fixed, paraffin-embedded 
(FFPE) tissue produces optimal morphology for histological assessment, but this technique may 
not preserve RNA integrity^^. While the literature suggests that frozen (FR) tissue is optimal for 
the extraction of high quality RNA^^’̂ °, this has not been shown for FR cervical tissue. 
Numerous techniques and commercially available kits exist for RNA extraction from FR tissue^*' 
and some have been utilized for cervical specimen extraction^^'^’̂ . However, the integrity of the 
RNA and the reproducibility of the techniques are often overlooked. Current literature does not 
provide a consensus for the optimal protocol for high quality RNA extraction, particularly from 
FR cervical specimens. In addition, the importance of LCM techniques for studying specific cell 
populations has resulted in the optimization of tissue preparation protocols specifically for 
LCM^^'^°, but it has not been demonstrated that these work well for cells obtained from cervical 
tissue.
The quality of data obtained from qRT-PCR experiments is greatly influenced by RNA 
integrity, RT conditions, housekeeping gene (HKG) selection and transcript abundance. The type 
of primers used for RT can also significantly alter the complementary DNA (cDNA) yield and 
specificity^\ While normalization of qRT-PCR-derived expression levels requires an appropriate 
HKG for compensating for differences between samples^^’̂ ,̂ HKG validation is required for each 
tissue typê "*. Furthermore, low transcript amounts represent an obstacle for simultaneous 
analysis of multiple targets or low-expressing genes and thus several methods exist for 
amplifying mRNA transcripts extracted from tissue samples^^'^^. However, none of these
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parameters have been described or optimized for gene expression analysis in cervical samples.
1.12 Research Rationale
Interferons are a common biological treatment option for many cancers as well as for 
HPV-associated diseases, but current IFN treatments have not been optimized as evidenced by 
the progression of the disease and the existence of treatment-limiting side effects. The novel 
IFN-k may improve upon existing therapeutics. Cervical tissue, the main constituent of which is 
the squamous keratinocyte, represents an ideal context in which to study IFN-k expression in 
response to a viral infection as HPV infects the squamous epithelium, the cell-type that chiefly 
expresses IFN-k. The requisite methods for detecting low-expressing IFNs in cervical samples 
and microdissected cervical epithelium are not described in current scientific literature, which 
made it necessary to develop and/or optimize these methods ourselves. To our knowledge, the 
expression of IFN-k in ex vivo cervical tissue has never been investigated. Further, the change of 
expression of this novel anti-viral mediator as a result of HPV infection has also never been 
examined in cervical tissue or isolated cervical epithelium and stroma. Together, with novel 
technological advancements for low-abundant gene expression analysis in cervical tissue, the 
detection and analysis of cell-specific IFN-k mRNA in HPV-associated cervical disease 
represents highly original research.
1.13 Hypotheses
We expected a disparate IFN gene expression profile with disease progression resulting 
from an HPV-induced alteration in the host-cell antiviral activity and IFN-k to be expressed 
uniquely compared to other IFNs due to its distinct signaling characteristics. We also expected 
LCM to reveal the involvement of both cervical epithelium and stroma in the observed IFN 
expression patterns of IFNs.
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1.14 Research Aims
1) To characterize tissue samples as morphologically normal, dysplastic or
cervical carcinoma tissue, as well as to test samples for HPV in order to 
establish a HPV negative normal group and to determine HPV types present 
in dysplastic and carcinoma tissues.
2) To develop optimal methods for sample storage, RNA extraction, cDNA
amplification and qRT-PCR for the detection of low-abundant interferon 
genes in cervical biopsy tissue and laser capture microdissected cervical 
kératinocytes.
3) To determine the effects of HPV on IFN gene expression in ex vivo cervical
tissue by analyzing IFN mRNA levels in normal, dysplastic and malignant 
cervical tissue as well as LCM-derived HPV+ and HPV- cervical 
kératinocytes using qRT-PCR.
4) To establish the IFN mRNA profile using qRT-PCR in human primary
kératinocytes, cervical cancer-derived cells lines and in the periphery of 
patients using human PBLs for supportive experiments.
5) To reveal the specific cell types involved in the observed IFN expression by
analyzing the IFN mRNA levels using qRT-PCR in normal, dysplastic and 
carcinoma epithelium and stroma isolated using LCM.
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2.0 MATERIALS AND METHODS
2.1 Sample Preparation
2.1.1 Cell Lines
Near-diploid immortalized foreskin kératinocytes (NIKS)^^ in the presence or absence of 
the Human Papillomavirus type 16 (HPV 16) E6®° or E7 oncogene were used in initial 
experiments to mimic normal and diseased cervical tissue to assess HKG suitability and cDNA 
amplification uniformity. Cervical carcinoma cell lines HeLa (ATCC, CCL-2, HPV 18+), SiHa 
(ATCC, HTB-35, HPV 16+), CaSki (ATCC, CRL-1550, HPV 16+ and HPV 18+ related 
sequences), M E-180 (ATCC, HTB-33, HPV39+) and C-33 A (ATCC, HTB-31, HPV-) were 
used for supportive experiments. All cell lines were grown in culture to 70% confluency prior to 
harvesting.
2.1.2 Biopsy Material
FR and FFPE normal and dysplastic cervical biopsies were obtained with written consent 
from women attending the Colposcopy Clinic at the Thunder Bay Regional Health Sciences 
Centre between November 2005 and November 2006. FR cervical carcinoma biopsies were 
obtained from the Cancer Centre at the Thunder Bay Regional Health Sciences Centre between 
November 2006 and December 2007 or the Ontario Tumor Bank in May, 2008. Biopsies were 
either snap frozen in liquid nitrogen and transferred to -80°C or immediately submerged in 10% 
(v/v) buffered formaldehyde solution for 3 hours at room temperature. The tissue was then 
dehydrated by submerging the tissue into ascending grades of ethanol (70%, 80%, 95% and 
100% v/v in water), then with 100% (v/v) xylene followed by wax-impregnation with paraffin^\ 
FR cervical tissue was sectioned on a cryostat (Leica CM 1850, Leica Microsystems, Richmond 
Hill, ON, Canada), maintaining tissue temperature at -20°C using Tissue Tek™ embedding
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medium (O.C.T. Compound, Sakura Finetek, Torrance, California, USA) while FFPE cervical 
tissue was sectioned using a microtome (Leica 1720 digital microtome, Leica Microsystems). 
Tweezers, brushes and surfaces were cleaned with DEPC-treated 70% (v/v) ethanol between 
specimens to reduce RNAse activity and RNA cross-contamination. Ten micometre thick tissue 
sections were processed for hematoxylin and eosin staining®^ and subsequent histopathological 
diagnosis by the same pathologist (Dr. Nicholas G. Escott). Additional 10 pm thick sections 
were used for HPV testing and stained immunocytochemically for p l6  for detection of HPV 
infection. Tissue samples were diagnosed as morphologically normal, dysplastic or cervical 
carcinoma. Samples were grouped into the following categories; HPV negative normal tissue 
(n=12), low-grade dysplastic tissue (n=9), high-grade dysplastic tissue (n=10) and HR HPV 
positive cervical carcinoma tissue (n=2).
2.1.3 Peripheral Blood Lymphocytes
PBLs and monocytes were isolated from whole blood specimens using Ficoll separation 
(Ficoll-Paque™ PLUS; GE Health Care, Piscataway, New Jersey, USA) according to the 
specified protocol for lymphocyte isolation. Briefly, blood was layered on top of Ficoll and 
centrifuged at 1750 rpm for 40 minutes. Lymphocytes and monocytes were isolated from the 
Ficoll, plasma, and red blood cells, containing granulocytes layers and washed with PBS. Pellets 
were frozen at -20°C along with RPMI (RPMI 1640 medium, catalogue # 23400-021, Invitrogen, 
Burlington, Ontario, Canada), human serum and dimethyl sulfoxide (Sigma-Aldrich, Oakville, 
Ontario, Canada).
2.2 DNA Extraction
Three methods were used to extract DNA from cell lines, cervical biopsy specimens and 
microdissected material. These include an in-house method, the Arcturus PicPure™ DNA
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Isoltion Kit (Arcturus Microgenomics, Molecular Devices, Sunnyvale, California, USA) and the 
Qiagen QIAamp® DNA micro kit (Qiagen, Mississauga, ON, Canada). The in-house method 
involved the addition of 50 pi of DNA digestion buffer (50 mM Tris-HCl, 1 mM EDTA, 0.5% 
(v/v) Tween 20, pH 8.5) to the samples along with 0.2 mg/ml proteinase K (Roche, Mississauga, 
ON, Canada) and incubation at 65°C for 4 hrs, 95°C for 5 minutes and then centrifugation at
13,000 rpm for 5 minutes. Isolation of DNA using the Arcturus and Qiagen methods followed 
the recommended protocols for isolation from cell pellets and/or tissue samples. All extracted 
DNA was stored at -20°C until used.
2.3 Polymerase Chain Reaction
Approximately 100 ng of DNA extracted from NIKS was used to optimize PCR 
conditions for the detection of the P-globin gene for sample integrity moitoring. Various 
concentrations of MgCla, nucleotide bases (dNTPs; dATP, dGTP, dCTP, dTTP) and primers 
were tested along with varying annealing temperatures until a discrete 110 bp P-globin band was 
visualized by agarose gel electrophoresis. Optimized PCR conditions for the detection of P- 
globin are as follows; 4.0 mM MgCl%, 200 pM dNTPs, 0.1 pM forward and reverse p-globin 
primers (PC03 [5116-035] and PC04 [5116-036] primers, Sigma-Aldrich), 1.25 units of Taq 
polymerase (Amplitaq DNA polymerase. Applied Biosystems, added to equal amounts of 
Taqstart Antibody ([S1476], Becton Dickinson and Company, Oakville, ON, Canada) and IX 
PCR buffer (Applied Biosystems). PCR reactions of 25 pi diluted using nuclease free water 
(PI 195, Promega Corporation, Madison, WI, USA) were incubated in a thermal cycler (2720 
Thermal cycler. Applied Biosystems) under the following condtions; 94°C for 4 minutes, 40 
cycles of 94°C for 1 minute, 60°C for 1 minute and 72°C for 2 minutes, and then 72°C for 7 
minutes. PCR products were analyzed using a 1.5% (w/v) agarose (Certified PCR agarose 161-
35
3104, Bio-Rad Laboratories, Mississauga, ON, Canada) gel. DNA integrity from microdissected 
cervical epithelium was subsequently analyzed by amplifying the HKG P-globin using PCR from 
DNA extracted, as described above, from LCM material.
2.4 P16 Staining
Sections from biopsy specimens were stained for p 16 over-expression using the CINtec 
p i 6 immunocytochemsitry staining kit (CINtec pl6INK4a Cytology Kit; mtm laboratories, 
Westborough, MA, USA). Diffuse staining was considered p l6  positive, while specimens 
displaying discrete focal positivity were deemed negative. A negative control was included in 
each case where the primary antibody was omitted to reduce false positive results.
2.5 Immunohistochemistry
Samples used for LCM analysis were stained for CD4/CD8+ cells in the stroma epithelial 
layers. Primary antibodies specific for CD4/CD8 cell surface markers (MT310 (CD4), DK25 
(CD8), DAKO, Glostrup, Denmark) were diluted in DAKO real antibody diluent (DAKO, 
S2022) at 1:100 in PBS and 100 pi was added to the tissue section, then incubated for 1 hour at 
room temperature. Samples were then washed in ice cold IX PBS. The secondary mouse 
antibody conjugated to an Alexa 594 fluorphore was diluted in antibody diluentl:800 and then 
added to the section (100 pi) and incubated in the dark for 30 minutes. Sections were washed in 
IX PBS as before and mounted with medium containing DAPI.
2.6 RNA Extraction
RNA was extracted from 1 0 x 1 0  pm thick FFPE and FR cervical tissue sections as well 
as from 1 x 10® NIKS using three different methods: Sigma TriReagent® (Sigma-Aldrich), 
following the recommended protocol for extraction using 1 ml of TriReagent® with the addition 
of 20 pg of RNAse-free glycogen carrier (Fermentas Lifesciences, Burlington, ON, Canada) and
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with 2 units of terminal DNAse treatment (Ambion); the Ambion RNAqueous “-4PCR (Ambion 
Inc., Austin, Texas, USA), following the described method for extraction from FR tissue/cell 
pellets; and the Arcturus PicoPure™ RNA Isolation kit following the protocol described for 
isolation from CapSure® Macro LCM Caps (Arcturus) with the addition of 13.6 Kunitz units of 
RNAse-free DNAse treatment (Qiagen, catalog# 79254) and slight modifications when using 
tissue sections®^. Briefly, 100 pi of extraction buffer (XB) was added to samples and incubated at 
42°C for 30 minutes. The addition of an extra 50 pi of XB made tissue homogenization more 
manageable when working with tissue sections. One hundred microlitres of 70% (v/v) ethanol 
was then added (1:1 ratio with XB) to the cell extract and RNA isolation was performed as 
described in the protocol. The Arcturus kit was also used for RNA extraction from 
microdissected samples using 8 pm thick FR tissue, following the recommended protocol for use 
with CapSure® Macro LCM caps (Arcturus)
2.7 Nucleic Acid Quantification and Integrity Assessment
The quality and quantity of RNA extracted from cell lines and cervical tissue was 
assessed using the Bio-Rad Experion™ Automated Electrophoresis System. RNA integrity from 
samples was assessed by visual inspection of the electropherograms^^ as well as the digital gel 
images. Samples possessing distinct 18S and 28S ribosomal peaks in the electropherogram®^ as 
well as sharp, abundant 18S and 28S ribosomal RNA (rRNA) bands in the gel images, were 
indicative of high RNA integrity. Calculated rRNA 28S/18S ratios did not always correlate with 
superior images^"^ and are therefore reported here but were not used for sample integrity 
assessment.
High sensitivity chips (Experion™ RNA HighSens Analysis Kit, Bio-Rad) were used to 
analyze RNA from LCM-obtained samples and from FFPE and FR cervical biopsy sections
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whereas standard sensitivity chips (Experion™ RNA StdSens Analysis Kit, Bio-Rad) were used 
to assess RNA from cell lines. When specified, initial cell line cDNA was quantified using a 
Nanodrop spectrophotometer (ND-1000, NanoDrop Technologies, Thermo Fisher Scientific, 
Wilmington, Delaware, USA) and RNA integrity was later confirmed using the Experion™ (data 
not shown).
2.8 Laser Capture Microdissection
The Arcturus Histogene™ Frozen Section Staining Kit was used to prepare samples for 
microdissection. FR biopsy sections were fixed, stained and dehydrated following the Arcturus 
method with slight modifications. Briefly, IX ProtectRNA™ (ProtectRNA™ RNAse Inhibitor 
500x concentrate, catalog number R7397, Sigma-Aldrich) was added to the staining solution 
(Culling 1984) and tissue was dehydrated as normal with the addition of an extra 100% (v/v) 
ethanol step to acquire intact RNA®*. Tissue sections were allowed to dry for up to 3 hours prior 
to capturing 5,000 to 25,000 cells in 1,000 to 5,000 captures using CapSure® Macro LCM caps. 
Typically one tissue section was adequate to obtain 1,000 LCM captures of cervical 
kératinocytes, while 4-5 sections were required to obtain 5,000 LCM captures. Five thousand 
captures were taken for IFN gene expression analysis. Macro caps were cleaned of unwanted 
debris using CapSure pads (Arcturus) prior to being deposited into 1.5 ml microfuge tubes for 
RNA extraction. The laser spot size was consistently 15 pm in diameter whereas the laser power 
and duration varied slightly between sections (ranging from 80 to 95 mW and 0.65 to 0.8 
millisecond duration). LCM images were taken at lOX magnification.
2.9 Reverse Transcription and cDNA Amplification
RNA isolated from samples was reverse transcribed to complementary DNA (cDNA) 
using the High Capacity cDNA Archive Kit (Applied Biosystems) according to the
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manufacturer’s directions with random hexamer primers. All RT reactions were performed in 18 
pi volume. RNA from cell lines whose cDNA was not amplified was reverse transcribed at 20 
ng/pl while RNA from cell lines requiring cDNA amplification and cervical biopsy tissue was 
reverse transcribed at 4 ng/pl. RNA isolated from microdissected cervical samples was reverse 
transcribed at 0.06-2.8 ng/pl, depending on acquired LCM sample RNA concentration. Fifty 
nanograms of cDNA from NIKS and whole biopsy sections as well as between 0.75 and 35 ng of 
cDNA from microdissected tissue was amplified using the TaqMan® PreAmp Master Mix Kit 
(Applied Biosystems), unless otherwise specified. For amplification uniformity assessment, 7.5 
ng of cDNA from NIKS and biopsy sections as well as 2.5 ng of cDNA from an LCM sample 
was amplified and compared to 7.5 ng of unamplified cDNA from NIKS and biopsy material and
1.8 ng of unamplified cDNA from the LCM sample. NIKS were used in initial experiments to 
determine the optimal amplification conditions. Uniform transcript amplification was assessed 
within each sample by comparing unamplified versus amplified gene expression between two 
genes using the AACt method, as described (Applied Biosystems TaqMan® PreAmp Master Mix 
Kit Protocol, Appendix A; checking preamplification uniformity). A AACt value of 0 ± 1.5 
indicated uniform amplification
2.10 Quantitative Real-Time Polymerase Chain Reaction
Reactions were carried out according to the qRT-PCR protocol specified in the TaqMan® 
PreAmp Master Mix Kit. Amplified or unamplified cDNA (6.25 (il) was added to each reaction. 
Triplicate reactions of 25 pi volume were added to a 96-optical well plate (Applied Biosystems) 
and incubated at standard qRT-PCR conditions (50°C for 5 minutes, 95°C for 10 minutes and 
then cycled at 95°C for 15 seconds and 60°C for 1 minute for 40 cycles). TaqMan® gene 
expression assays for hypoxanthine phosphoribosyltransferasel (HPRTl), P-actin, phospholipase
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A (PLA), 18S ribosomal subunit (18S), beta-2-microglobulin (B2M), IFN-y, IFN-P and IFN-K 
were used. Negative controls where cDNA was omitted or the enzyme was missing in the RT 
reaction were run to monitor for contamination or non-specific primer binding. A positive 
control was included on every plate to control for variation between runs. Candidate HKGs were 
chosen based on an extensive literature review. After demonstrating that its expression was 
unaffected by HPV infection, target Ct values were normalized to HPRTl. Relative 
quantification of target genes was performed using auto Ct and baseline settings and a threshold 
of 0.20 (Applied Biosystems 7300/7500/7500 Fast Real-Time PCR System Software).
2,11 Statistical Analysis
The Relative Expression Software Tool (REST©)^®'^’, designed for highly sensitive 
quantification, was used for comparing gene expression between two groups when analyzing 
patient tissue, using reaction efficiencies set to 1. An efficiency value of 1 assumes all reactions 
are 100% efficient. Suitability of HKGs in patient tissue was assessed by setting target gene 
values to zero to measure only the HKG expression. Unpaired, two-tailed student’s t-tests were 
used for cell line analysis as well as alongside REST when analyzing tissue samples. Student’s t- 
tests appeared more appropriate when analyzing small sample sizes. ANOVA tests were used 
when analyzing gene expression in more than two groups. The Fisher’s exact t-test was used 
when assessing the prevalence of gene expression between two groups. For all statistical tests, p- 
values < 0.05 indicated a statistical difference in expression.
40
3.0 RESULTS
3.1 Sample Size and Material Characterization
3.1.1 RNA Integrity o f  Samples
Samples used in this study were thoroughly tested for RNA integrity. Of all biopsy 
specimens tested, 79.4% displayed suitable RNA integrity and were therefore included in this 
study (Table 1). Cell lines were of the highest quality, as seen in Figure 5, where the Experion 
gel images (Figure 5A) show minimal degradation and distinct ribosomal subunit bands and the 
electropherogram (Figure 5B) showed a high 28S peak relative to 188. Whole biopsy specimens 
also displayed good RNA integrity, as see in Figure 5C, but with more degradation compared to 
cell lines. The whole biopsy electropherogram illustrated slight degradation with a lower 288 
ribosomal subunit peak (Figure 5D). LCM samples also showed adequate RNA integrity as 
distinct ribosomal subunit bands still exist in the gel image with no appreciable amount of 
degradation (Figure 5E). However the LCM electropherogram demonstrated slightly more 
degradation from whole biopsy specimens with a lower 288 subunit peak (Figure 5F). PBLs 
isolated from patient blood specimens displayed high RNA integrity similar to cell lines (Figure 
5G).
3.1.2 HPV Typing
Of the 34 samples included in this study, 15 (45%) were infected with a HR HPV type. 
Of these 45%, 40% were infected with HPV 16 detected using PCR and HPV 16 E6 specific 
primers, as seen in Figure 6A. The remaining 60% were infected with an unknown HR HPV 
type. In the sample size, there were 13 samples (39.4%) that were HPV- when tested in a PCR 
using HPV-consensus primers (Figure 6B), HPV 16-specific primers or stained for p l6 . Of these 
13 samples, 12 were morphologically diagnosed as normal by pathologist Dr. Nicholas Escott. 
One low-grade sample (sample 80) was devoid of HPV infection with our tests. The one
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Table 1. Case number, morphological diagnosis, use, and HPV status for cervical tissue samples
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X = p l6  negative, + = p l6  positive, - =not analyzed for sample 
lsil=low-grade epithelial lesion 































































Figure 5. RNA integrity of samples. Experion™ gel images of ribosomal subunits for cell lines 
(HeLa, 28S/18S ratio 2.27; C33A, 1.95; SiHa, 1.95; MelSO, 1.84; CaSki, 2.20)(A), full biopsy 
tissue (Sample 84, 1.12; 86, 1.20; 87, 1.06; 88, 0.90; 158, 1.21) (C), laser capture microdissected 
material (Sample 169e, 1.24; B29e, 1.24, B2e, 1.28; B7e, 0.00; 84e, 0.45) (E) and peripheral 
blood lymphocytes (Sample 67, 1.08; 79, 1.48; 161, 1.05; 158, 0.93) (G). The top thicker band 
represents the 28S ribosomal subunit while the lower thinner band represents the 18S ribosomal 
subunit. Representative Experion™ electrophero grams of ribosomal subunit peaks in cell lines 
(B), full biopsy sections (C) and laser capture microdissected material (F). RNA from cell pellets 
(A and G) was extracted using the Ambion extraction method while RNA from tissue samples 





Figure 6. HPV detection in cervical biopsy material. HPV 16 (A) and HPV consensus (B) 
sequence detection in FFPE cervical whole biopsy samples. Representative positive results 
shown for 3 HPV 16+ samples (cases 96, 74, 158) and 5 HPV+ samples (cases 83, 152, 151, 84 
and 158). DNA from FFPE biopsy tissue was extracted using the in house method and run in 
PCRs using HPV 16 E6-specific primers (450 bp) as well as HPV consensus primers (180 bp) 
and run on a 1.5% (w/v) agarose gel. PCR conditions were as follows; Ix PCR buffer, 4 mM 
MgCl, 200 |iM dNTPs, 1 |iM HPV 16 1/2 primers or 0.1 pM HPV consensus primers, 1.25 units 
of Taq polymerase. Ta of 60°C.
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carcinoma specimen HPV tested (n=l) in this study was HR HPV+. All samples were sent away 
for HPV genotyping to identify those with multiple HPV infections and to genotype the 
remaining 60% of HR HPV infected samples and the remaining carcinoma. P16 staining was 
used as a second analysis of HR HPV infection in case PCR primers were not sensitive enough 
to detect HPV sequences. Of the diseased cases stained for p l6  positivity, 86.6% were positive 
for p l6  overexpression, an example of which is shown in Figure 7. Furthermore, 100% (4/4) of 
HPV 16+ samples (results obtained from PCR) stained for p l6  resulted in positivity, indicating 
that p l6  staining was a reliable measure of HR HPV infection in this study.
3.1.3 Infiltrating CD4/CD8+ Cell Status
The cases used for LCM analysis of gene expression (n=25) (Figure 29: Appendix A) 
were stained for CD4/CD8+ positive infiltrating cells to reveal the extent of infiltrate in both the 
epithelium and stroma in these cases. CD4 and CD8 are cell surface markers on a range of 
leukocytes, including monocytes and dendritic cells, and are prominent markers for helper T and 
cytotoxic T lymphocytes, respectively. For microdissection, it was important to characterize the 
material excised in the epithelial layers and to know what kinds of cells were present in the 
dermis. Of the 24 cases analyzed, 100% of them showed CD4/CD8+ infiltrating cells in the 
epithelium and 96% showed positivity in the stroma. However, a range of positive CD4/CD8 
infiltrate results existed within sample categories (Figure 8, Table 2). Some HPV- normal tissue 
exhibited a high amount of infiltrate in both the epithelium and stroma, whereas other normal 
HPV- specimens exhibited low levels of infiltrate. Two normal cases (75 and 169) exhibited 
substantially higher amounts of infiltrate in the epithelium than any of the diseased tissues. Many 
dysplastic cases showed a moderate amount of infiltrate in the epithelium and there seemed to be 
no correlation with amount of infiltrate and the grade of the lesion.
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Figure 7. p l6  immunocytochemistry for the detection of high risk HPV infection in cervical 
samples. Cervical tissue samples were stained for p i 6 overexpression (brown) using the CINtec 
pl6INK4a cytology kit (ref #110). Negative cervical epithelium (left) shows no staining, 
whereas the presence of HR HPV infection in a cervical lesion (right) is indicated by diffuse 
brown staining.
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Case 75 Normal HPV-Case 64 LSIL HR HPV+
Case B22 LS L HPV+ Case 79 Normal HPV
Case B33 HSIL HPV16+ Case 169 Norma HPV-
Figure 8. Infiltrating CD4/CD8+ cells in the cervical microenvironment. Sections o f three 
normal and three dysplastic cervical tissue stained for infiltrating CD4/CD8+ lymphocytes (red). 
Cervical cell nuclei are shown in blue (DAPI stain). White arrows denote the cervical squamous 
epithelium while the grey arrows denote the underlying stroma. Images are at 20X 
magnification.
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Table 2. Summary of the presence of CD4/CD8 positive infiltrating cells in tissue samples.
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3.2 Method Development for IFN-k Detection in Cervical Material: DNA
3.2.1 Optimal PCR conditions
For the process of HPV typing cervical samples, the integrity of sample DNA must be 
monitored to control for false negative results. The HKG P-globin was used to monitor DNA 
integrity in samples. To obtain a highly spécifié P-globin band, standard PCR conditions were 
modified to yield an optimal reaction. Increasing the MgCl2 concentration (Figure 9A), 
decreasing the dNTP concentration (data not shown), increasing the annealing temperature (T a ) 
to 60°C (data not shown), and decreasing the primer concentration (Figure 9B) generated a 
specific (3-globin product in cell lines. The optimal PCR conditions for ^-globin detection are; 
50-100 ng DNA, Ix PCR buffer, 4 mM MgCl, 200 |iM dNTPs, 0.1 |iM primers, 1.25 units of 
Taq Polymerase and a Ta of 60°C, incubated at 94°C for 4 minutes and then 40 cycles of 94°C 
for 1 minute, 60°C for 1 minute and 72°C for 2 minutes, and then 72°C for 7 minutes.
3.2.2 DNA Extraction Methods: NIKS and Tissue Samples
Four extraction methods were used to extract DNA from NIKS. This was initially done to 
obtain an optimal extraction technique that could be extended to cervical biopsy sections for the 
purposes of HPV typing. The extraction techniques tested included an in-house method 
(consisting of a home-made buffer composed of 50 mM Tris-HCl [pH 8.5], 1 mM EDTA and 
0.5% Tween20 (v/v)), the Qiagen QIAamp DNA mini kit, the Arc turns Pico Pure DNA Isolation 
kit and the Qiagen QIAamp Micro kit. Extending from preliminary results (data not shown), two 
dilution series were performed using two of the extraction techniques, the home-made buffer 
technique and the Areturus Pico Pure DNA Isolation Kit, to assess the sensitivity of the 
extraction methods. DNA was extracted from 10® NIKS transfected with different HPV 16 E6 
variants and serial diluted 1:10 seven times to yield a DNA dilution series from approximately
50
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Figure 9. Optimization of PCR conditions for beta-globin detection. 1.5% (w/v) agarose gels 
show increasing the annealing temperature [MgClz] plus decreasing the nucleotide concentration 
and primer concentration increases the specificity of the PCR reaction for the 110 bp beta globin 
band. A. Products were run with a 1 |uM primer concentration and different MgCli 
concentrations. B. Products were run with 0.1 p.M beta globin primer pair and the same MgCli 
concentrations as in gel A. Products run in pairs; PCR products obtained from DNA extracted 
from approximately 1,000 (Lanes A & C) and 100,000 (Lanes B & D) NIKS transfected with the 
14/78/83 E6 gene. DNA was extracted using the home-made extraction buffer technique. Lane L 
represents the 100 bp DNA ladder.
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10® cells to one cell. (3-globin bands were obtained from DNA extracted from the 5'^ dilution 
(-100 cells) using the Areturus method. The in-house method yielded (3-globin bands from the 
6'^ dilutions (-10  cells), as seen in Figure 10. The results indicate that to obtain optimal DNA 
yield from a small amount of cells, our in-house extraction method is optimal for extracting 
DNA from NIKS. This technique was extended for DNA extraction from PR and FFPE cervical 
biopsy tissue with much success, as demonstrated in Figure 6.
3.2.3 DNA Extraction Methods: LCM material
Extracting high quality DNA from LCM samples allows for HPV testing to be performed 
on isolated cell populations. Cervical biopsy tissue prepared for LCM using the Aretums method 
described for DNA extraction allows for quality DNA isolation from 1, 10, 100 and 1,000 LCM 
captures (representing approximately 5, 50 500 and 5,000 cells respectively), as demonstrated in 
Figure 11. Both the home-made extraction buffer technique and the QIAamp micro DNA 
extraction kit were used to extract DNA from LCM cervical tissue. The QIAamp kit generated (3- 
globin bands at a lower-limit of 1 LCM capture (Figure 11) while the home-made buffer failed 
to generate a band using material from one LCM capture (data not shown). This indicates that 
despite optimal DNA extraction results using the home-made extraction buffer for NIKS (Figure 
10), the Qiagen QIAamp micro kit is the optimal method for extracting high quality DNA from 
LCM-excised cervical tissue. Furthermore, the sensitivity of LCM for analyzing DNA integrity 
is demonstrated by the presence of a (3-globin band in just one LCM capture (lane 2; 
approximately 5 cells).
3.3 Method Development for IFN-k Detection in Cervical Material: RNA
3.3.1 Sample Storage and RNA Extraction
RNA degradation, resulting from inadequate tissue storage and/or extraction techniques
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Figure 10. HPV detection in cervical samples using agarose gel electrophoresis. 1.5% (w/v) 
agarose gels show the 110 bp beta globin gene in a DNA dilution series using a combination of 
NIKS + HPV 16 E6 variant cells. DNA was extracted using a home-made extraction method. 
Lane L represents a 100 bp DNA ladder. A. Lanes represent PCR products obtained from DNA 
extracted from approximately 10® to 10  ̂NIKS using Ipl (A) or 8pl (B) DNA input. B. Lanes 
represent PCR products obtained from DNA extracted from approximately 10  ̂ to 1 cells using 
Ipl (A) or 8pl (B) DNA input. All PCR products were generated using same conditions; Ix PCR 
buffer, 4 mM MgCl, 200 |iM dNTPs, 0.1 pM primer pair, 1.25 units Taq polymerase, T a= 6 0 °C .
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Figure 11. Sensitivity of LCM for detection of quality DNA. A 2.0 % (w/v) agarose gel 
showing the 110 bp beta globin gene from LCM captured cervical cells extracted using the 
Qiagen QIAamp micro kit. Products are presented in pairs with Ipl (A) and 8|il (B) DNA input. 
From left to right, lanes represent PCR products obtained from DNA extracted from 1 capture to 
1,000 LCM captures. The last lane (Pos) represents a positive control for beta globin. All PCR 
products were generated using same conditions; 1 x PCR buffer, 4 mM MgCl, 200 pM dNTPs, 
0.1 pM primers, 1.25 units Taq polymerase, Ta=60°C.
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could significantly alter the resulting transcript profile within a sample. Several methods exist to 
assess RNA integrity, including denaturing gel electrophoresis, UV spectrophotometry and 
microfluidics. Traditional gel electrophoresis requires large amounts of RNA to visualize 
ribosomal bands while UV spectrophotometry assesses sample purity not RNA integrity. 
Microfluidic gel electrophoresis, such as the Bio-Rad Experion™, permits integrity assessment 
of small amounts of RNA. This system was therefore used to assess RNA integrity in cervical 
biopsies, stored in different conditions, and extracted using various techniques as well as in laser 
capture microdissected cervical epithelium.
RNA extracted from FR cervical biopsy tissue showed higher integrity than RNA 
extracted from FFPE cervical tissue (Figure 12A). Using standard sensitivity Experion™ chips 
(lanes 1-6), RNA integrity was assessed between two FR samples (lanes 1-2) and 4 FFPE 
samples (lanes 3-6). No visible rRNA bands were found in the FFPE samples. However, as seen 
in lanes 7 and 8, the accuracy of the integrity assessment was greatly improved for the intact FR 
samples when high sensitivity Experion^^ chips were used as demonstrated by the more 
pronounced rRNA bands shown. This data demonstrates that FR tissue specimens preserved the 
integrity of RNA whereas formalin-fixation procedures degraded it. However, out of all FR 
biopsy specimens tested, only 74% yielded high-quality (data not shown), indicating that RNA 
integrity is not equal between samples despite identical extraction and storage conditions. The 
Areturus isolation method was optimal for the extraction of high quality RNA from small 
amounts of FR cervical biopsy tissue (Figure 12B) compared to the Sigma and Ambion 
methods. No visible rRNA bands were present when the Ambion or Sigma methods were used 
for extraction. Conversely, RNA yield and quality from NIKS was highest when using the 
Ambion method, as seen in Figure 5A.
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Figure 12. RNA integrity of cervical tissue using different sample storage and extraction 
methods. A. Integrity of RNA in FR versus FFPE cervical tissue. RNA was extracted from FR 
cervical biopsy sections (Lanes 1, 2, 7, 8) and FFPE cervical sections (Lanes 3, 4, 5, 6) using the 
Areturus PicoPure™ RNA Isolation Kit. RNA in lanes 1 through 6 was measured using standard 
sensitivity Experion™ chips. RNA from FR samples A and B were re-measured using an 
Experion™ high sensitivity chip (lanes 7 and 8) resulting in 28S/18S rRNA ratios of 0.83 and 
1.49 respectively. B. Integrity of RNA from 6 frozen cervical biopsies extracted using three 
different extraction kits. The Areturus (lanes 1 and 4), Sigma (lanes 2 and 5) and Ambion (lanes 
3 and 6) extraction kits were tested. Experion™ standard sensitivity chips (lanes 3 and 6) and 
high sensitivity chips (lanes 1, 2, 4, 5) were used. “L” represents the RNA ladder (Kb). 
Representative gel images are shown. 28S/18S rRNA ratios for samples A and D were 1.49 and 
0.83 respectively. Two bands represent the 28S (top) and 18S (bottom) rRNA.
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3.3.2 RNA Integrity and Tissue Morphology o f LCM Samples
LCM selects for specific cells within a heterogenous cell population. When target genes 
of interest are cell-type specific, such as IFN Kappa (IFN-k), which is mainly expressed in 
epithelial cells^\ it is crucial to isolate only those cells of interest to gain an accurate assessment 
of the gene expression profile within a tissue microecology. Obtaining intact RNA from 
microdissected samples is equally as important for accurate gene expression analysis. Cervical 
biopsy tissue prepared for LCM using the Areturus method allowed isolation of high quality 
RNA from cervical kératinocytes using 1,000 or 5,000 LCM captures (Figure 13A), as distinct 
28S and 18S rRNA bands can be seen in both LCM samples. Furthermore, the morphology of 
the tissue was adequate for differentiation between cell types within the tissue (Figure 13B-D), 
as cervical kératinocytes were easily differentiated from surrounding stroma. These data 
demonstrate that LCM tissue preparation using the reported method provides suitable tissue 
morphology and high-quality RNA for use in downstream applications.
3.3.3 Reverse Transcription
Random hexamer primers were more suitable for RT than oligo(dT) primers. HPRT-1 
and p-actin gene expression was analyzed in NIKS transduced with the HPV 16 E6 oncogene or 
an empty vector. Differences between the two conditions for both HPRTl and p-actin were 
smaller (student’s t-test, p=0.011 and p=0.039 respectively) when using random hexamer 
primers compared to oligo(dT)s, as shown in Figure 14A. RT primer pairs were also assessed in 
normal and dysplastic cervical biopsy tissue (Figure 14B). Similar to cell lines, random hexamer 
primers produced more favorable results as smaller differences in HPRTl and P-actin mRNA 
levels exist between normal and dysplastic tissue when random hexamers were used (student’s t- 
test, p= <0.0001 and p= <0.0001 respectively).
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Figure 13. RNA integrity and tissue morphology of laser capture microdissected cervical 
tissue. A. Intact RNA obtained from 1000 (lane 2; 190 pg/|il RNA, 28S/18S= 0.38) and 5000 
(lane 3; 630 pg/|il, 28S/18S= 1.50) laser capture microdissected cervical kératinocytes. Two 
bands represent 28S (top) and 18S (bottom) rRNA. B. Cervical biopsy section illustrating 
cervical kératinocytes (top arrow) and stroma (bottom arrow). C. 1,000 LCM captures before 
film was lifted from slide. D. Excised epithelial region after film was lifted from slide (black 
arrow). Representative gel and histological images are shown.
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Figure 14. The effect of different RT primer pairs on HKG expression. A. P-actin and 
HPRTl gene expression measured by qRT-PCR in NIKS +/- the HPV 16 E6 oncogene with 
eDNA reverse transcribed using random hexamer or oligo(dT) primers. RNA was extracted from 
NIKS using the Ambion RNAqueous®-4PCR kit. eDNA was quantified using a Nanodrop. B P- 
actin and HPRTl gene expression measured in normal and dysplastic cervical biopsy tissue with 
eDNA reverse transcribed using random hexamer or oligo(dT) primers. RNA was extracted from 
tissue sections using the Areturus PicoPure™ RNA Isolation Kit. Values represent raw qRT-PCR 
Ct value ± SD. eDNA values were obtained from initial RNA values measured using the 
Experion™.
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3.3.4 HKG fo r  Normalization between Samples
The use of HKGs for normalization between samples is critical, especially when using 
heterogenous tissue samples. While all qRT-PCR studies utilize HKGs for normalization 
between samples, few studies determine an optimal reference gene for specific tissues. 
Expression of the HKGs HPRTl, P-actin, 18S, B2M and PLA was analyzed in NIKS in the 
presence or absence of an HPV 16 oncogene (Figure ISA). HPRTl, B2M and PLA mRNA levels 
were statistically similar (student’s t-test, p > 0.05) between the two cell lines. By contrast, 
expression of P-actin and 18S genes was significantly different between the two cell lines 
(student’s t-test, p < 0.05). The expression of HPRTl and PLA was significantly similar (REST, 
p=0.955 and p=0.367 respectively) between normal (n=4) and dysplastic (n=12) cervical whole 
biopsy tissue, as demonstrated in Figure 15B.
3.3.5 cDNA Amplification
cDNA amplification involves the uniform amplification of specific target genes of 
interest within a sample and increases the ability to detect low expressing gene transcripts within 
a suitable range using qRT-PCR. The Taqman® PreAmp Master Mix Kit (Applied Biosystems) 
uniformly amplified cDNA transcripts within NIKS, whole cervical biopsy sections and 
microdissected cervical epithelium (Figure 16A) as all AACt values were less than 1.0. Using 
NIKS, the optimal cDNA amplification conditions were determined to be 14 cycles using 50 ng 
of cDNA template since the AACt value still indicated amplification uniformity for genes when 
the cDNA concentration was lowered and the cycle number was increased (Figure 16B).
3.3.6 Sensitivity o f qRT-PCR and LCM fo r  IFN Detection
qRT-PCR allows for the simultaneous detection, real-time amplification and 
quantification of RNA transcripts. Utilizing the TaqMan® (Applied Biosystems) methodology
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Figure 15. Housekeeping gene suitability for normalization across cervical disease states. A.
HPRTl, P-actin, 18S, B2M and PLA housekeeping gene expression in NIKS +/- HPV 16 E6 
measured using qRT-PCR using unamplified cDNA. HPRTl (p=0.955), B2M (p=0.367) and 
PLA (p=0.065) were expressed the same between the cell lines. cDNA was quantified using a 
Nanodrop. Asterisks indicate significant difference in expression (p < 0.05) between the cell 
lines. cDNA input concentrations were determined using the Experion™ and were not always 
equal between genes.B. HPRTl and PLA housekeeping gene expression in normal (n=4; patients 
92, 93, 100, 169) and dysplastic (n=12; patients 74-166) cervical tissue. HPRTl (p=0.796) and 
PLA (p=0.728) are expressed the same between the control and dysplastic group. Values 
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Figure 16. Uniform cDNA amplification in cervical samples. A. HPRTl and PLA gene 
expression in NIKS, cervical biopsy sections and laser capture microdissected cervical 
kératinocytes was analyzed before (UA) and after (PA) cDNA amplification using qRT-PCR. 
Amplification uniformity was assessed using the delta delta Ct method. HPRTl and PLA in 
NIKS (AACt= 0.03), cervical sections (AACt= 0.93) and microdissected cervical kératinocytes 
(AACt= 0.14) respectively were amplified uniformly. B. Uniform cDNA amplification in NIKS. 
cDNA from NIKS was left unamplified or amplified for 10 or 14 cycles using 50 or lOOng of 
cDNA. qRT-PCR gene expression analysis was performed for HKG HPRTl and target gene 
IFN-k using both unamplified and amplified cDNA. Representative cases are shown for tissue 
samples. 5,000 LCM captures were taken for microdissected cervical samples. Values represent 
raw qRT-PCR Ct value ± SD. cDNA input concentrations were determined using the Experion™.
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and reagents for gene expression analysis, this method was used to analyze the gene expression 
of HKGs and target genes in samples to determine transcript input and LCM sensitivity for the 
detection of low-expressing IFNs. Whole biopsy sections from 3 cases of cervical dysplasia were 
analyzed by qRT-PCR (Figure 17A). Using the methods described, all IFNs were expressed 
within a detectable range for qRT-PCR analysis. In general, the expression level of IFNs 
followed the order of: IFN-k < IFN-P < IFN-y. One thousand LCM captures (~1 ng of total 
RNA) were sufficient to measure HKGs and target genes present at only a moderate level, such 
as IFN-y, in cervical epithelium. However, for the detection of low expressing genes, such as 
IFN-P and IFN-k, 5,000 LCM captures were required (-10 ng of total RNA), as illustrated in 
Figure 17B.
3.4 Interferon Gene Expression Profile in Normal, Dysplastic and Carcinoma Tissue
3.4.1 IFN-re Expression
IFN-k gene expression in whole cervical biopsy specimens was detected more often in 
dysplastic tissue (10/16; 62.5%) and carcinoma tissue (2/2; 100%) (Table 3, Figure 18) than in 
normal tissue (2/8; 25%), however the prevalence was not significantly different (Fisher’s exact 
t-test, p=0.50 (ns) and p=0.133 (ns), respectively). When present, the expression level of IFN-K 
was significantly higher in dysplastic tissue compared to normal HPV- tissue (REST, p=0.031) 
and in carcinoma tissue compared to dysplastic tissue (student’s t-test, p=0.022) (Table 4). 
Overall, IFN-k gene expression prevalence increased with lesion progression, although not 
significantly. However, the level of IFN-k gene expression increased significantly as the lesion 
progresses from normal to invasive carcinoma (ANOVA, p=0.006), as seen in Figure 19.
3.4.2 IFN-P Expression
IFN-P was expressed in 26/26 (100%) of all whole biopsy samples, however the IFN-P
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Figure 17. Sensitivity of qRT-PCR and LCM for the detection of Interferon gene 
expression in dysplastic cervical tissue. A. Three cases of cervical dysplasia were analyzed for 
IFN gene expression using qRT-PCR and 50ng of RNA from whole biopsy sections. cDNA 
input values were determined from RNA values measured using the Experion™. B. 
Housekeeping and target IFN mRNA detection using qRT-PCR and 1,000 and 5,000 LCM 
captures of cervical kératinocytes yielding 1 ng and 10 ng of RNA. Values represent raw qRT- 
PCR Ct values ± SD. cDNA input concentrations were determined using the Experion™. The 
horizontal dashed line represents the upper limit for qRT-PCR detection. A representative case is 
shown.
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Table 3. Summary of the prevalence of IFN-y, -P and -K mRNA in normal (n=8), dysplastic 
(n=16) and cervical carcinoma(n=2) whole biopsy tissue samples.
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Figure 18. IFN-K gene expression in cervical biopsy sections. Full biopsy sections of normal 
cervical tissue (n=8), low-grade cervical dysplastic tissue (n=8), high-grade cervical dysplastic 
tissue (n=8) and cervical carcinoma (n=2) were analyzed for IFN-k mRNA levels using qRT- 
PCR. Vertical bars represent the average delta qRT-PCR Ct value ± SD for each case. 
Percentages indicate prevalence. cDNA input concentrations were determined using the 
Experion™. Asterisks indicate significant difference in expression levels between the groups.
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Table 4. Statistical test results for EFN gene expression in normal, dysplastic cervical and 
carcinoma biopsy tissue. Student’s t-test results are displayed at the top, REST software results 
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Figure 19. Average IFN-k expression in normal, dysplastic and carcinoma full biopsy 
tissue. Full biopsy sections of normal (n=8), dysplastic (n=16) and cervical carcinoma tissue 
(n=2) were analyzed for IFN-k mRNA levels using qRT-PCR. Vertical bars represent the 
average delta qRT-PCR Ct value ± SD. cDNA input concentrations were determined using the 
Experion ™.
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gene expression level was significantly down-regulated in dysplastic tissue compared to normal 
HPV- tissue (REST, p=0.009, student’s t-test, p=0.007) (Table 4, Figure 20). Although the 
prevalence of IFN-P gene expression remains unchanged with the progression of the lesion 
(Table 3), the gene expression level was significantly different in normal, dysplastic and 
carcinoma tissue (ANO’VA, p=0.039), as seen in Figure 21, where IFN-P mRNA levels were 
highest in normal tissue, decreased in dysplastic tissue and then increased in carcinoma tissue.
3.4.3 IFN-yExpression
IFN-y gene expression was present in 26/26 (100%) samples (Table 3) and its expression 
level remained unchanged with disease state as no significant differences in IFN-y mRNA levels 
were found between normal, dysplastic or carcinoma tissue samples (Table 4), as illustrated in 
Figure 22. IFN-y mRNA levels followed a similar trend as IFN-P where gene expression 
decreased in dysplastic tissue from normal tissue and then increased in carcinoma tissue 
(ANOVA, p=0.876 (ns)) (Figure 23).
3.4.4 Relative Expression oflF N s
The expression of all three IFNs in relation to each other and their relative expression in 
whole cervical biopsy tissue are illustrated in Figure 24 and Figure 25 respectively. The 
expression levels of these IFNs follow the pattern IFN-k < IFN-p < IFN-y in normal and 
dysplastic tissue, however in one carcinoma specimen the expression pattern was opposite; IFN-y 
< IFN-P < IFN-k . A significant difference in expression between the two carcinoma samples was 
observed for IFN-y, -P and -k (student’s t-test, p=0.0006, p=0.003 and p=0.0008 respectively) 
(Figure 26). There was a trend that IFN-k mRNA levels became closer to the expression levels 
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Figure 20. IFN-p gene expression in cervical biopsy sections. Full biopsy sections of normal 
cervical tissue (n=8), low-grade cervical dysplastic tissue (n=8) and high-grade cervical 
dysplastic tissue (n=8) were analyzed for IFN-P mRNA levels using qRT-PCR. Vertical bars 
represent the average delta qRT-PCR Ct value ± SD for each case. Percentages indicate 
prevalence. cDNA input concentrations were determined using the Experion ™. Asterisks 
indicate significant difference in expression levels between the groups.
77





Figure 21. Average IFN-p expression in normal, dysplastic and carcinoma full biopsy 
tissue. Full biopsy sections of normal (n=8), dysplastic (n=16) and cervical carcinoma tissue 
(n=2) were analyzed for IFN-p mRNA levels using qRT-PCR. Vertical bars represent the 
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Figure 22. IFN-y gene expression in cervical biopsy sections. Full biopsy sections of normal 
cervical tissue (n=8), low-grade cervical dysplastic tissue (n=8) and high-grade cervical 
dysplastic tissue (n=8) were analyzed for IFN-y mRNA levels using qRT-PCR. Vertical bars 
represent the average delta qRT-PCR Ct value ± SD for each case. Percentages indicate 
prevalence. cDNA input concentrations were determined using the Experion ™. No statistical 
significant difference between the groups.
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Figure 23. Average IFN-y expression in normal, dysplastic and carcinoma full biopsy tissue.
Full biopsy sections of normal (n=8), dysplastic (n=16) and cervical carcinoma tissue (n=2) were 
analyzed for IFN-y mRNA levels using qRT-PCR. Vertical bars represent the average delta qRT- 
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Figure 24. All analyzed IFNs in cervical biopsy sections. Full biopsy sections of normal 
cervical tissue (n=8), dysplastic tissue (n=16) and cervical carcinoma tissue (n=2) were analyzed 
for IFN-y,-P, and -K mRNA levels using qRT-PCR. Values represent the average delta qRT-PCR 
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Figure 25. Relative expression of all analyzed IFNs in cervical biopsy sections. Full biopsy 
sections of normal cervical tissue (n=8) and dysplastic tissue (n=16) were analyzed for IFN-y,-P, 
and -K mRNA levels using qRT-PCR. Values represent relative expression values (1/Ct). cDNA 
input concentrations were determined using the Experion™.
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Figure 26. IFN gene expression in whole carcinoma tissue. Full biopsy sections of two 
cervical squamous carcinoma cases were analyzed for IFN-y,-p, and -K  mRNA levels using qRT- 
PCR. Values represent the average delta qRT-PCR Ct value ± SD. cDNA input concentrations 
were determined using the Experion ™. Carcinoma #1 is sample CC02 and carcinoma #2 is 
sample CC04. Asterisks represent significant differences in expression between samples.
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3.5 In Vitro IFN Expression
3.5.1 Kératinocytes and Cervical Cancer-Derived Cell Lines
Due to the low availability of cervical carcinoma tissue, cervical cancer-derived cell lines 
were utilized for a further investigation into IFN expression in the malignant phenotype. IFN-k 
gene expression was strong in primary kératinocytes and present in immortalized kératinocytes 
devoid or transduced with an HPV oncogene (Figure 27). However, IFN-k expression was lost 
in some carcinoma-derived cell lines, namely HeLa, SiHa and the HPV-negative C33A cell line. 
IFN-k mRNA levels were higher than IFN-P in HPV 16+ CaSki cells but found at a lower level 
in the Me 180 cell line (Figure 27). IFN-P gene expression was present in all the cell lines at a 
moderate level, whereas IFN-y was absent in almost every cell line except SiHa and C33A, 
notably where IFN-k expression was lost. A significant difference in IFN-k and IFN-p 
expression existed between NIKS + E6 and NIKS + E7 (student’s t-test, p= < 0.0001 and p= <
0.0001 respectively).
3.6 Peripheral Expression of IFNs in Patients
3.6.1 Peripheral Blood Lymphocytes
To investigate the IFN expression profile in the periphery of patients, PBLs and 
monocytes, were isolated from patients who displayed IFN-k expression in their whole biopsy 
samples. IFN-k gene expression was not found in the PBLs of patients with normal or dysplastic 
cervical tissue, however IFN-p and -y were found at similar levels (student’s t-test, p=0.643 and 
p=0.715) in 6/6 (100%) cases, as shown in Figure 28. TNF-a gene expression was analyzed 
alongside the IFNs to show the expression levels of the IFNs in relation to another gene. TN F-a 
gene expression was similar in the periphery of patients with normal or dysplastic tissue 
(student’s t- test, p=0.697). IFN-p and IFN-y were consistently expressed at lower levels in the
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Figure 27. IFN gene expression in cell lines. Primary kératinocytes (n=l), immortalized 
kératinocytes transduced with an empty vector (n=l; NIKS) or an HPV oncogene (n=2: NIKS+ 
HPV 16 E6; NIKS + HPV 16 E7) and cervical cancer-derived cell lines (n=5; HeLa, HPV18; 
CaSki, HPV 16; SiHa, HPV16; M el80, HPV39; C33A, HPV-) were analyzed for IFN-y, -P, and - 
K mRNA levels using qRT-PCR. Values represent the average delta qRT-PCR Ct value ± SD of 
two experiments. cDNA input concentrations were determined using the Experion™.
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Figure 28. IFN and TNF-a gene expression in peripheral hlood lymphocytes. Peripheral 
blood lymphocytes and monocytes were isolated from whole blood specimens obtained from 
patients whose full biopsy sections revealed IFN-k expression. PBLs were analyzed for IFN-y, - 
P, and -K as well as TN F-a mRNA levels using qRT-PCR. Values represent the average delta 
qRT-PCR Ct value ± SD. cDNA input concentrations were determined using the Experion™.
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periphery than TNF-a.
3.7 LCM Analysis of IFN Expression in Cervical Tissue
3.7.1 Microdissected Cervical Epithelium and Stroma
To investigate the cell-specific gene expression of IFNs, cervical epithelium and stroma 
were isolated using laser capture microdissection. It should be noted that all excised epithelium 
cases did contain some infiltrating CD4/CD8-t- cells, the extent of which was variable, and could 
not be avoided during the microdissection process. The characterization of CD4/CD8-t- infiltrate 
in each case was documented in Figure 8 and Table 2. IFN-k was detected in normal, dysplastic 
and cervical carcinoma epithelium, as seen in Figure 29A and in Appendix 1: Table 5, as well 
as in the stroma in 12.5 % (1/8) of dysplastic cases and in the one carcinoma sample analyzed 
(Figure 29B, Appendix 1: Table 5). Differences in the expression levels exist but could not be 
statistically analyzed due to the low sample size and expression prevalence.
IFN-p gene expression was detected in 91.7% (11/12) of normal epithelium, 70% (7/10) 
of dysplastic epithelium and 100% (1/1) of carcinoma epithelium (Appendix 1: Table 5) and in 
100% of normal (12/12) and carcinoma (1/1) stroma and in 87.5% (7/8) of dysplastic stroma. 
IFN-p gene expression prevalence was not statistically different between the cases (Fisher’s 
exact t-test, p >0.05). The expression levels of IFN-p did not differ between normal and 
dysplastic epithelium or stroma (student’s t-test, p=0.152 and p= 0.438 respectively) (Appendix 
1: Table 6). The carcinoma LCM tissue could not be statistically analyzed due to the low 
samples size. However, a general trend existed for IFN-p; IFN-p gene expression was decreased 
in diseased cervical epithelium (Figure 30A), however stromal IFN-p expression appeared to 
increase with HPV infection (Figure 30B).
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Figure 29. Cell type-specific IFN-k expression in normal, dysplastic and carcinoma tissue.
Cervical epithelium (A) and stroma (B) were excised from normal, dysplastic and cervical 
carcinoma whole biopsy samples using LCM and the mRNA levels of IFN-k was analyzed using 
qRT-PCR. Vertical bars represent the average delta qRT-PCR Ct value ± SD. Standard error bars 
are present when 2 or more values are available. cDNA input concentrations were determined 
using the Experion™.
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Figure 30. Cell type-specific IFN-p expression in normal, dysplastic and carcinoma tissue.
Cervical epithelium (A) and stroma (B) were excised from normal, dysplastic and cervical 
carcinoma whole biopsy samples using LCM and the mRNA levels of IFN-P was analyzed using 
qRT-PCR. Vertical bars represent the average delta qRT-PCR Ct value ± SD. Standard error bars 
are present when 2 or more values are available. cDNA input concentrations were determined 
using the Experion™.
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IFN-y gene expression was detected in 83.3% (10/12) of normal epithelium, 90% (9/10) 
of dysplastic epithelium and 100% (l / I )  of carcinoma epithelium (Appendix 1: Table 5) and in 
100% of normal (12/12), dysplastic (8/8) and carcinoma (1/1) stroma. IFN-y gene expression 
prevalence was not statistically different between the cases (Fisher’s exact t-test, p >0.05). The 
expression levels of IFN-y did not differ between normal and dysplastic epithelium or stroma 
(student’s t-test, p=0.20 and p= 0.163 respectively) (Appendix 1: Table 6). The carcinoma LCM 
tissue could not be statistically analyzed due to the low sample size. However, a general trend 
existed for IFN-y; IFN-y gene expression appeared to increase in diseased cervical epithelium 
(Figure 31A), yet stromal IFN-y expression decreased drastically in carcinoma tissue (Figure 
31B).
3.8 IFN Gene Expression in Repeated LCM Samples
LCM was repeated in seven cases in different tissue layers within the same area to 
analyze the intra-individual distribution of gene expression present within samples (Figure 36: 
Appendix 1). IFN-k expression was noticeably different in 42.9% (3/7) of the LCM repeats, 
whereas IFN-(3 and IFN-y expression differed noticeably in only 28.6% (2/7) of the repeated 
cases. Insight into the moderate focal expression of IFN-(3, IFN-y and, to a higher extent IFN-k, 
is illustrated in Figure 36 A, C and G (for IFN-k), Figure 36 E and F (for IFN-(3) and Figure 
36 D and E (for IFN-y) where the repeated LCM experiments result in different IFN expression 
profiles.
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Figure 31. Cell type-specific IFN-y expression in normal, dysplastic and carcinoma tissue.
Cervical epithelium (A) and stroma (B) were excised from normal, dysplastic and cervical 
carcinoma whole biopsy samples using LCM and the mRNA levels of IFN-y was analyzed using 
qRT-PCR. Vertical bars represent the average delta qRT-PCR Ct value ± SD. Standard error bars 




In this study, using cell lines, cervical tissue and microdissected cervical cells, we 
assessed various sample preparation and analysis techniques that can influence gene expression 
studies to devise optimal methods for analyzing low-abundant genes in cervical samples. 
Following method optimization, a thorough analysis of IFN gene expression was performed 
using whole cervical biopsy tissue, microdissected cervical epithelium and stroma as well as 
human kératinocytes and human cervical cancer-derived cell lines.
4.1 Method Development
The method of tissue storage was assessed for the preservation of high quality RNA in 
cervical biopsy specimens. In agreement with previous studies^^’®°’**, our data strongly suggested 
that FR cervical tissue was optimal for obtaining a high quality and quantity of RNA (Figure 
12A) whereas FFPE tissue processing caused considerable degradation and low yield, possibly 
due to nucleic acid cross-linking with proteins, covalent modifications and strand breaks*^. RNA 
from FFPE tissue was not suitable for gene expression analysis. For the detection of quality and 
quantity of RNA in the range of 20-40 ng/p.1, the Experion™ high sensitivity kit produced more 
reliable results than the standard kit.
Published methods for extracting RNA differ with respect to reagents, filter columns and 
the amount of sample required. Furthermore, many published techniques claiming high quality 
RNA isolation from FR tissue either relied only on expression of HKGs^^’®°, A260 / Aigo ratio 
or did not perform RNA quality assessment at all®®’®*’̂ .̂ Here we show that contrary to previous 
results with FR tissue®^’̂ '̂̂ ,̂ the modified Arcturus RNA extraction method was optimal for the 
extraction of high quality RNA compared to the Ambion and Sigma methods for cervical biopsy 
sections (Figure 12B). Although limited material prohibited a direct comparison of all
92
techniques with the same sample, representative images are shown for each extraction method 
(Figure 12B). The Trizol extraction method had previously been shown to produce poorer RNA 
quality when using small amounts of cervical cells^^. Small amounts of sample material may 
limit RNA yield for some extraction methods. Although the amount of tissue used was in the 
range specified by the Ambion and Sigma kits, high quality RNA was only obtained using the 
Arcturus kit, which is designed for extraction from microdissected samples. This indicates that 
for extraction from small amounts of cervical tissue, as seen previously in prostate tissue^^, 
methods optimized for extraction from microdissected samples produced favorable results.
Tissue preparation protocols for LCM and FR tissue often differ in many respects, 
including the dehydration procedure and the staining solutions. Recent evidence suggests that 
inclusion of an RNAse inhibitor*^ as well as a prolonged 100% (v/v) ethanol incubation^^’*̂  
generated higher quality RNA from microdissected samples. It was previously argued that the 
protocol described in the Arcturus Histogene™ Frozen Section Staining Kit is not adequate for 
obtaining high quality RNA from FR LCM samples^*. This could be due to active RNAses 
present in the tissue and/or improper dehydration leading to RNA degradation. Together with 
recent results utilizing similar methodology and FR specimens^"^’*̂ ,̂ our data demonstrate that a 
modified version of the Arcturus staining method combined with the Arcturus extraction method 
was highly suitable for morphological assessment and high quality RNA extraction from LCM- 
obtained cervical kératinocytes (Figure 13). This finely-tuned technique is a significant 
advancement, as obtaining intact RNA from LCM samples is often challenging, and our 
modification may be extended for the preparation of other FR tissues for LCM. RNAlater®-lCE 
(Ambion), tested for its impact on RNA integrity preservation, rendered the biopsy specimen 
difficult to section and had no impact on sample RNA integrity (data not shown). In addition.
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cervical tissue scraped off the slide displayed similar HKG expression compared to LCM- 
obtained cervical material from the same specimen (data not shown), indicating that the 
microdissection process did not compromise RNA integrity.
The type of primers used for RNA RT is critical for the quality of cDNA produced^^ and 
depending on the type of primers utilized, differences exist in the calculated mRNA copy 
numbers^^. Oligo(dT) primers are widely used for priming cDNA reactions, however, recent 
evidence suggests they are markedly less sensitive than random primers for the RT process^^. 
Although random primers may present considerable problems for detecting transcripts present at 
low levels within a sample^*, this method may introduce less bias in the resulting cDNA 
compared to oligo(dT) primers or target-specific primers due to the exclusion of hairpins or RNA 
secondary structures'^. Random hexamer primers were chosen for RT of RNA to cDNA as these 
primers resulted in minimal differences in HKG expression between samples and slightly higher 
mRNA levels compared to RT using oligo(dT) primers (Figure 14). Random hexamer primers 
are thus preferred when preparing samples for the comparison of low-expressing gene levels 
between pathologic conditions.
HPRT is a commonly used reference gene, previously utilized for the study of low-level 
cytokine expression^"* and cervical cancer*°°. HPRT has been verified as an optimal normalizer 
between samples in colon, prostate, breast, skin and bladder tissue**** but had not been 
established as a suitable normalizer between normal and diseased cervical tissue. We 
demonstrated that HPRTl is the optimal HKG for normalization compared to p-actin, B2M, 18S 
and PLA in NIKS transduced or devoid of the HPV 16 E6 oncogene (Figure 15A) as well as in 
cervical tissue in the presence or absence of HPV (Figure 15B). Relatively constant expression 
of HKGs in specimens is also indicative of sample integrity at this stage of sample processing.
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We found that PLA was also a suitable HKG in cervical tissue, though its expression may vary in 
the presence of high IFN protein'**^ and therefore may change in virus-infected tissue. HPRT was 
reported to represent the mean expression of many commonly used normalizing genes****, 
eliminating the need to use multiple genes for normalization. It is suitable for use with sensitive 
detection methods***  ̂and, similar to our data, HPRT has been shown to exhibit a low expression 
level suitable for the measurement of low expressing genes****, such as IFN-k.
While several methods exist for transcript amplification, they are often tedious and time- 
consuming. cDNA amplification is comparatively simple but its utility has never been reported 
in cervical samples for the analysis of multiple low-expressing target genes. Our data 
demonstrated that cDNA amplification significantly increased the expression level of target 
genes within NIKS, whole biopsy specimens and laser capture microdissected samples versus the 
expression levels obtained using unamplified cDNA (Figure 16A). Furthermore, determining the 
optimal amplification conditions (Figure 16B) (i.e., the number of cycles and the least amount of 
input cDNA required for target mRNA detection using qRT-PCR) greatly increased the ability of 
our techniques to measure target genes in limited amounts of cervical samples. We have shown 
that a reasonable amount of RNA isolated from cervical specimens, with the aid of cDNA 
amplification, permitted detection of all IFNs within a suitable qRT-PCR level (< 35 Ct) in both 
whole cervical sections (Figure 17A) and microdissected cervical kératinocytes (Figure 17B). 
IFN-k gene transcripts were not detectable in cervical biopsy tissue or microdissected 
kératinocytes using unamplified cDNA (data not shown) and, along with IFN-(3, was not 
detected in microdissected cervical kératinocytes using amplified cDNA from 1,000 LCM 
captures (Figure 17B). This is a significant sensitivity advancement and, to our knowledge, this 
is the first time IFN-k detection has been demonstrated in cervical kératinocytes from human
95
cervical biopsy specimens.
The development of precise methodology for measurement of cell-specific targets is 
instrumental for experimental pathologists to investigate the molecular profile of disease. The 
methods described herein were crucial for the comprehensive analysis of interferons in cervical 
tissue and likely could be extended to other keratinocyte-based investigations. Combined with 
high-throughput gene expression technologies, such as cDNA microarrays, these methods could 
lead to improvements in immunological profiling and disease diagnosis.
4.2 Interferon Expression in Patients
To our knowledge, this study is the first of its kind to show IFN-k gene expression in 
cervical tissue, with respect to HPV as well as in microdissected cervical kératinocytes and 
dermal stroma using qRT-PCR. Further, this study has characterized the regulation of IFN-k 
gene expression in response to HPV infection and cervical disease progression and also provided 
insight into specific cell types implicated in this observed change in expression within the 
cervical microenvironment. Additionally, this study is the first to demonstrate the relationship 
between three IFNs, with respect to novel IFN-k, in cervical tissue. The distinct relative 
expression levels of these IFNs, regardless of HPV infection, illustrates the differences between 
the subclasses of IFNs. Further, the expression of IFN-k in relation to IFN-p, in terms of relative 
expression and HPV-induced expression, highlights the uniqueness of IFN-k as a type I IFN. A 
relationship exists between decreased IFN-P expression and increased IFN-k expression with 
cervical disease progression, suggesting an alternate expression of the type I IFNs, a relationship 
which, to our knowledge, has also never been documented previously.
Our results demonstrate that the mRNA levels of IFN-k, a novel type I IFN, are 
significantly increased in dysplastic and carcinoma tissue compared to normal HPV- ceiwical
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tissue (Figure 19). Similarly, IFN-k mRNA levels have previously been detected in resting 
primary kératinocytes and upregulated in virus-induced kératinocytes**. In contrast to our results, 
IFN-k protein expression was not detected in healthy skin tissue^^. However the post- 
transcriptional regulation of IFN-k has not been characterized in cervical tissue. Further, in other 
studies IFN-k expression has shown variable results with respect to viral infection. For example, 
in the central nervous system, levels of IFN-k were unaffected by infection with Theiler’s virus, 
a picornavirus, or a mutant La Crosse virus, an arbovirus***"*, however IFN-k was capable of 
mediating anti-viral protection against two families of RNA viruses, encephalomyocarditis, a 
picornavirus, and vesicular stomatitis, a virus of the Rhabdoviridae family, in human dermal 
fibroblasts* * and against a hepatitis C virus replie on cell line^*. Our study is the first to analyze 
IFN-k expression response upon infection by a DNA virus. The consequences of DNA viral 
infection are infrequently discussed in the scientific literature, as most studies involving a viral 
inducer focus on RNA viruses and associated ligands. This study demonstrates that DNA viruses 
can have a similar effect on innate immune system regulation as RNA viruses with regard to 
IFN-k, as the effects of HPV in cervical tissue is similar to that of dsRNA-treated 
kératinocytes**.
IFN-k exhibits similar antiviral activity^* and utilizes the same type I IFN receptor and 
regulatory element as other type I IFNs** but differs in its expression and signalling 
characteristics^*. Along with differences in expression and signaling, the IFN-k gene is located 
adjacent to the type I IFN cluster** and its sequence is structurally different than all other IFNs**. 
Although the pathways involved in the activation of IFN-P and -y are known, the transcriptional 
regulation of IFN-k is unknown. Our data indicate that, while IFN-P mRNA levels decrease with 
HPV infection and progression to cancer, IFN-k gene expression is upregulated in diseased
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tissue. We reason that because the IFN-k gene harbors structural differences from other type I 
IFNs, the observed differences in gene expression patterns between IFN-p and IFN-k could be 
due to distinct pathways/transcription factors governing IFN-k gene regulation which may not be 
inhibited by HPV, as is seen with IFN-p. Instead, the effect of HPV on IFN-k in cervical tissue is 
likely gene transcription promoting, as seen in dsRNA induced kératinocytes**. Further studies 
are required to investigate post-translational IFN-k expression to determine the biological 
effects, if any, of the observed increase in IFN-k gene expression in HPV-infected cervical 
tissue.
In contrast to IFN-k, IFN-P, another type I IFN, was detected at the mRNA level in all 
tissue specimens, and, as previously shown using RT-PCR*** ,̂ its expression is down-regulated in 
virally-infected tissue in the present study (Figure 21). Similarly, IFN-P and IFN-a transcription 
was shown to be downregulated in kératinocytes infected with HPV 16 using RT-PCR analysis"* .̂ 
The down-regulation of IFN-P gene expression is consistent with the known inhibitory effects of 
HPV on transcription factors governing IFN expression. HPV E6 and E7 oncoproteins bind to 
transcription factors critical for mediating IFN signaling in response to a viral infection. For 
example, HPV type 16 E6 binds and inactivates the transcription factor IRF-3"** while HPV 16 E7 
inactivates IRF-l"*’ ; both of which result in a reduction in IFN-P gene expression during HPV 
infection. The observed increase in IFN-P gene expression in cervical carcinoma tissue 
compared to dysplastic tissue could be attributed to changes in immunogenicity common to the 
cervical malignant phenotype. The decreased expression of HPV early gene E2, which is 
associated with viral genome integration in severe cervical lesions, leads to a substantial increase 
in HPV E6 and E7 expression. The increase in expression of E6 and E7 could alter the 
immunogenicity of HPV viral proteins***  ̂ leading to a host-generated immune response against
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the virus which could trigger, for instance, an increase in IFN-(3 gene expression, as shown in 
carcinoma tissue in the present study. However, HPV has been shown to inhibit proteins 
involved in IFN-elicited anti-viral pathways, such as ISGF"̂ ® and JAK-STAT^^, which may 
prevent the generation of a beneficial IFN-(3 response and which may explain why increased 
IFN-(3 mRNA levels were associated with cervical carcinoma.
IFN-y, a type II EFN, has previously been demonstrated to be decreased in cervical 
dysplasia compared to normal tissue^^ and expressed at lower frequencies in invasive carcinoma 
compared to dysplastic tissue^^. In contrast, results of the present study indicate no significant 
difference in IFN-y gene expression levels or prevalence between normal, dysplastic and cervical 
carcinoma biopsy tissue (Figure 23). A trend exists where IFN-y does decrease in dysplastic 
compared to normal tissue; however, intra-individual variability for this gene was too high to 
enable statistical significance. IFN-y up-regulation has been implicated as a possible prognostic 
marker for the oncogenic potential of HR HPV^°^. The results of the current study indicate that 
decreased IFN-y expression does not represent a specific marker for HR HPV infection. 
However, there is a high prevalence of HR HPV infection in the dysplastic group of the present 
study (66.7%; 12/18), therefore the infectious HPV type could be a possible contributor to the 
high variability found in IFN-y gene expression levels in this study. IFN-y stimulation has 
previously been shown to induce IFN-k expression in monocytes^*^ and in human kératinocytes 
in vitro^^’̂ .̂ This relationship was not found ex vivo in the present study using cervical whole 
tissue biopsies (Figure 25). Tissue exhibiting high IFN-y levels did not display noticeably 
different IFN-k levels. This disparity further illustrates the uniqueness of IFN-K expression in the 
cervical microenvironment.
Using normal, dysplastic and cervical carcinoma full biopsy specimens, we have shown
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the gene expression levels of three prominent IFNs with respect to HPV infection using qRT- 
PCR. While IFN-P gene expression decreases with HPV infection, IFN-k mRNA levels 
substantially increase and IFN-y shows no significant change in expression. Although trends 
exist with the analysis of whole cervical biopsy tissue, multiple cell-types within the tissue 
sample may affect the analysis. Using microdissection to isolate cervical kératinocytes and 
stroma, which consist of a wide variety of different cell types including, dendritic cells, 
fibroblasts and monocytes, can provide insight into the cell-specific IFN response within the 
cervical microenvironment.
The isolation of cervical epithelium and stroma using LCM has allowed for the 
discrimination of specific cell populations involved in the observed change in gene expression. 
LCM revealed a correlation between gene expression of IFN-k in stromal cells and cervical 
disease progression. Epithelial IFN-k expression was present in normal, dysplastic and 
carcinoma tissue (Figure 29A). However, stromal expression of IFN-k was only present in 
dysplastic and carcinoma tissue (Figure 29B), indicating that HPV infection induces IFN-k 
expression in the dermal stroma. These results are similar to previous findings that the IS RE 
upregulation by IFN tau, another type I IFN, was found in the stroma in ovine endometrium^^^. 
An increase in stromal gene expression of IFN-k in response to HPV-infected cervical 
epithelium could be indicative of a host-generated immune response against HPV infection. 
While recruited infiltrating leukocytes may exhibit IFN-k expression, the consequences of the 
increase in IFN-k gene expression in these cells remains to be explored. Further experiments are 
required to identify the specific stromal cells responsible for this expression. Previous studies 
have shown IFN-k expression in resting monocytes and dendritic c e lls '\ but our data suggest 
that in the cervical microenvironment these innate immune cells do not inherently express IFN-k
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in normal stroma because CD4/CD8 + infiltrating cells were present in the majority (91.7%) of 
eases devoid of stromal IFN-k expression. While no differences were found in IFN-|3 (Figure 
30) or IFN-y (Figure 31) gene expression in isolated normal or dysplastic epithelium or stroma, 
this study demonstrates that, unlike previously shown", IFN-p mRNA levels are detected in 
resting keratinoeytes.
4.3 Interferon Expression in Cell Lines
IFN-k expression was very high in primary keratinoeytes compared to immortalized 
keratinoeytes and cervical cancer-derived cell lines (Figure 27). This demonstrates the intrinsic 
difference in the immune response present in skin versus the uterine cervix and further 
demonstrates the importance of developing sensitive techniques for the detection of IFN-k 
transcripts in cervical tissue. High levels of IFN-k expression relative to IFN-P in HPV 16+ 
CaSki cells substantiates the evidence that IFN-k levels were higher than other IFNs in an 
HPV 16+ cervical carcinoma specimen (Figure 26, CC02). These data indicate that perhaps HPV 
type 16, once integrated into the host genome, leads to a preferential induction of IFN-k. The 
HPV-negative cell line, C33A, shows no IFN-k gene expression and substantiates our claim that 
HPV is associated with an induction of IFN-k gene expression in cervical cells. However, IFN-k 
mRNA levels were undetectable in SiHa cells, which also contain one copy of integrated 
HPV 16, and HeLa cells, containing HPV18; results of which cannot be explained at present. 
While cell lines are useful for preliminary analyses of cell-signaling pathways, confirmation 
using ex vivo tissue, mouse models or an in vitro organotypic raft culture system is necessary. 
Further, given that previous studies have shown slight differences in IFN-P gene expression 
regulation between the HPV type 16 E6 and E7 oncoproteins''’’''*, we analyzed IFN-k gene 
expression in NIKS transduced with only HPV 16 E6 or HPV 16 E7. A significant difference in
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IFN-k mRNA levels was found between NIKS+E6 and NIKS+E7 (Figure 27). NIKS + E7 
displayed a significantly higher expression of IFN-k than NIKS + HPV 16 E6 and even NIKS + 
empty vector, indicative of a possible role of HPV 16 E7 in IFN-k gene activation. The 
promoting role of HPV 16 E7 for IFN-k gene expression indicates the involvement of unique 
factors governing IFN-k transcription that may be selectively activated by HPV E7.
4.4 Conclusions and Future Studies
The worldwide impact of HPV is significant as thousands of women succumb to HPV- 
associated cervical cancer each year. The recently approved prophylactic vaccine against 
common HR HPVs is not a treatment for cervical or any other HPV-associated cancer and is not 
beneficial to people already infected with HR HPV or immunocompromised patients. As a 
consequence, there is a great need for studies which characterize the effects of HPV on the 
immune system to aid in the development of patient-tailored treatment regimes. This study, 
describing the optimized methods for low-expressing gene detection combined with the HPV- 
associated upregulation of a novel type I IFN in human cervical tissue, represents novel 
technological advancements and insight for the area of immunological regulation of HPV- 
associated cervical disease.
IFNs are innate immunity mediators vital to the generation of an immune response 
against invading pathogens. Type I and II IFNs differ vastly in biological function and thus it 
was important to characterize the differences in biological expression levels of the two classes 
within HPV-infected cervical tissue. Although present at low levels within the normal, 
physiological cervical microenvironment, IFN-k gene expression is profoundly influenced by 
HPV infection, demonstrating the biological relevance of detecting this IFN at low levels. LCM 
has isolated a probable cause of the observed increase in IFN-k gene expression, shedding light
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on the importanee of the entire microenvironment in anti-viral defense. We have indieated an 
opposing relationship between the two type I IFNs analyzed in this study. This relationship 
emphasizes the unique expression pattern of IFN-k in cervical tissue and outlines a novel 
relationship between type I IFNs. Cell line and carcinoma tissue data indicate a possible role of 
HPV 16 E7 in promoting IFN-k gene activation. Lack of IFN-k expression in C33A cells further 
substantiates our data indicating the gene promoting effects of HPV in cervical cells.
As a result of this research, questions about the relevance of IFN-k gene expression now 
remain. Why is the expression of IFN-k, a potent anti-viral mediator, high in dysplastic and 
carcinoma tissue? What happens following IFN-k gene transcription that permits the disease to 
progress despite high active gene levels? Does IFN-k play a role in anti-papillomaviral activity? 
Do mRNA levels correlate with protein expression? What is the specific cell type responsible for 
the upregulation of IFN-k expression in the stroma? The question of the biological relevance of 
high gene transcription levels could be answered by evaluating IFN-k expression on the protein 
level in cervical tissue. However, to date, multiple IFN-k antibodies exist, all of which have been 
unsuccessful in specifically targeting IFN-k protein expression using immunohistochemistry for 
this study (data not shown). Furthermore, in situ hybridization along with staining for cell- 
speeifie markers in the stroma would be the most precise method to elucidate the responsible cell 
type.
In this study, we have made significant strides in characterizing the effects of HPV on 
IFN-mediated innate immunity. However, although characterizing the effects of HPV in ex vivo 
human tissue has its value, the effects on IFN-k during the full viral life cycle cannot be studied 
in this context. Mechanistic studies involving the active viral life cycle is an important step in the 
analysis of the effect of HPV on IFN-k and in vitro studies are now in progress which mimic the
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active HPV viral life cycle. Using an organotypic raft culture system with NIKS transfected with 
full length HPV16, the effect of HPV on IFN-k can be analyzed during both the productive and 
non-productive stages of the viral life cycle. The organotypic raft culture system will provide 
insight into the biological significance of IFN-k gene activation by permitting investigations 
during the active viral life cycle that eventually can be correlated with our ex vivo results using 
cervical biopsies. Furthermore, gene analysis in ex vivo cervical tissue may be influenced by co- 
infections with other HPV types or other microbial agents residing in the female uterine tract, 
such as cocci, fungi or other sexually transmitted infections that can be controlled for using the 
raft culture system.
This study has presented a thorough analysis of IFN-k gene expression in ex vivo cervical 
material and we now possess the necessary tools to further investigate the mechanistic role HPV 
plays in IFN-k gene regulation.
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6.0 APPENDIX A
6.1 Survey of Innate Immune Response in Microdissected Cervical Material
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Figure 32. Cell type-specific gene expression of IFNs and genes involved in innate immunity 
in individual normal HPV- cervical tissue samples. Cervical epithelium (dark grey bars) and 
stroma (light grey bars) were excised from whole cervical samples using LCM and the mRNA 
levels of 16 genes were analyzed using qRT-PCR. Samples A-K were analyzed for all 16 genes, 
while sample L was analyzed just for IFN expression. Ten cases involved both epithelim and 
stromal analysis, while 2 samples do not include stromal gene expression analysis.Values 
represent the average delta qRT-PCR Ct value ± SD. cDNA input concentrations were 
determined using the Experion™.
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Figure 33. Cell type-specific gene expression of IFNs and genes involved in innate immunity 
in individual dysplastic cervical tissue samples. Cervical epithelium (dark grey bars) and 
stroma (light grey bars) were excised from whole cervical samples using LCM and the mRNA 
levels of 16 genes were analyzed using qRT-PCR. Samples A-J were analyzed for all 16 genes, 
while sample K was analyzed just for IFN expression. Seven cases involved both epithelim and 
stromal analysis, while 4 cases include either epithelium or stromal gene expression analysis 
only. Values represent the average delta qRT-PCR Ct value + SD. cDNA input concentrations 
were determined using the Experion™.
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6.2 Prevalence of Gene Expression in LCM Cohort
Table 5. Summary of the prevalence of genes expressed in normal and dysplastic cervical
epithelium and stroma
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6.3 Statistical Differences in Gene Expression in LCM  cohort
Table 6. Statistical significance in gene expression in LCM samples: A comparison of innate 
immunity gene expression between normal and dysplastic epithelium and stroma
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* Results significantly higher for dysplastic or stroma tissue (where applicable) unless otherwise stated 
Bold values = statistically significant (-) =  could not be analyzed (e) = epithelium  
Carcinoma material not included (n=l)
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Figure 34. Summary of IFN gene expression as well as genes displaying significant differences 
in expression between normal HPV- and dysplastic cervical tissue. IFN-k (A), - 7  (B), -P (C), 
TLR 1 (D), 2 (E), 3 (F), 5 (G) and IL-10 (H) gene expression was measured separately in the 
epithelium and stroma of cervical tissue using laser capture microdissection. The mRNA levels 
of genes were analyzed using qRT-PCR. Values represent the average delta qRT-PCR Ct value ± 
SD. cDNA input concentrations were determined using the Fxperion ™. Asterisks indicate 
significant differences.
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6.4 Cell-specific Gene Expression in Cervical Carcinoma epithelium and Stroma
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Figure 35. IFN expression in cervical carcinoma epithelium and stroma. . IFN-k, -y, -p, 
TLR 1-9, IL-2,-4,-6,-10, and TNF-a gene expression was measured separately in the epithelium 
and stroma of cervical carcinoma tissue using laser capture microdissection. The mRNA levels 
of genes were analyzed using qRT-PCR. Vertical bars represent the average delta qRT-PCR Ct 
value ± SD. cDNA input concentrations were determined using the Fxperion™.
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Figure 36. A survey of gene expression in different tissue layers within 7 individual tissue 
samples. Cervical epithelium and stroma were excised from tissue samples separately on two 
occasions in the same region using LCM and the mRNA levels of 16 genes were analyzed using 
qRT-PCR. Dark grey bars indicate the first microdissection experiment and the light grey bars 
indicate the second microdissection experiment. Vertical bars represent the average delta qRT- 
PCR Ct value ± SD. cDNA input concentrations were determined using the Experion™.
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